CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (CNRS) (France)
ECOLE NATIONALE SUPÉRIEURE D'INGÉNIEURS DE CAEN (France)
Inventeur(s)
Mouaddib, Abdel-Ilah
Jeanpierre, Laurent
Abrégé
Methods of and systems for knowledge-based reasoning to establish a list of active objectives by an autonomous system. The method comprises accessing a list of active objectives; accessing a first database populated with static environment properties, the static environment properties defining properties of entities, the entities defining an environment in which the autonomous system is configured to operate; accessing a second database populated with dynamic environment properties comprising third computer-readable instructions generated by the autonomous system based on events having been observed by the autonomous system. Upon observing a new event, a new dynamic environment property is generated based on the new event and coherence checking is executed to assess whether the new dynamic environment property conflicts with at least one of the static environment properties, and, if so, the new dynamic environment property being identified as incoherent.
Centre National De La Recherche Scientifique (France)
Inventeur(s)
Ybert, Thomas
Delarue, Marc
Abrégé
The invention relates to variants of a DNA polymerase of the polX family capable of synthesizing a nucleic acid molecule without a template strand, or of a functional fragment of such a polymerase, comprising at least one mutation of a residue in at least one specific position, and to uses of said variants, in particular for the synthesis of nucleic acid molecules comprising 3′-OH modified nucleotides.
INSERM (INSTITUT NATIONAL DE LA SANTÉ ET DE LA RECHERCHE MÉDICALE) (France)
INSTITUT JEAN PAOLI & IRENE CALMETTES (France)
AIX-MARSEILLE UNIVERSITÉ (France)
CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE CNRS (France)
Inventeur(s)
Lachaud, Christophe
Combes, Sébastien
Abel, Sébastien
Audoly, Gilles
Berrada, Sara
Abrégé
The present invention relates to the field of oncology. laboratory tools and methods, and especially anti-tumor DNA crosslinking agents. Most patients with advanced solid tumors develop resistance to chemotherapy due to the ability of cancer cells to repair or tolerate sustained DNA damages. The inventors showed that the compounds according to the present invention allow the detection and visualization of alkylated DNA damages induced by PBDs without altering their DNA crosslinking ability. This enables the study of the effect and properties of PBDs. In particular, the present invention relates new derivates of PBD molecules and their synthesis. The present invention also relates to a method for visualizing DNA crosslinking: to a method for assessing the resistance of a tumor to a crosslinking agent and to a method for identifying a molecule or treatment for improving the efficiency of a crosslinking agent.
C12Q 1/6886 - Produits d’acides nucléiques utilisés dans l’analyse d’acides nucléiques, p.ex. amorces ou sondes pour les maladies provoquées par des altérations du matériel génétique pour le cancer
C07C 205/59 - Composés contenant des groupes nitro liés à un squelette carboné le squelette carboné étant substitué de plus par des groupes carboxyle ayant des groupes nitro et des groupes carboxyle liés à des atomes de carbone de cycles aromatiques à six chaînons du squelette carboné le squelette carboné étant substitué de plus par des atomes d'oxygène liés par des liaisons simples
C07D 207/22 - Composés hétérocycliques contenant des cycles à cinq chaînons, non condensés avec d'autres cycles, ne comportant qu'un atome d'azote comme unique hétéro-atome du cycle avec uniquement des atomes d'hydrogène ou de carbone liés directement à l'atome d'azote du cycle comportant une liaison double entre chaînons cycliques ou entre chaînon cyclique et chaînon non cyclique avec des hétéro-atomes ou avec des atomes de carbone comportant trois liaisons à des hétéro-atomes, avec au plus une liaison à un halogène, p.ex. radicaux ester ou nitrile, liés directement aux atomes de carbone du cycle
CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (France)
UNIVERSITE DE BORDEAUX (France)
INSTITUT POLYTECHNIQUE DE BORDEAUX (France)
Inventeur(s)
Prakasam, Mythili
Largeteau, Alain
Silvain, Jean-François
Abrégé
The present invention relates to a high-pressure method for preparing a metal monolith either as dense or as highly porous form, by rapid inductive heating hot pressing equipment. The method of the invention allows to obtain a metal monolith from metal powder without binder or any other additives
B22F 3/00 - Fabrication de pièces ou d'objets à partir de poudres métalliques, caractérisée par le mode de compactage ou de frittage; Appareils spécialement adaptés à cet effet
B22F 3/11 - Fabrication de pièces ou d'objets poreux
B30B 15/02 - Matrices; Garnitures ou montures appropriées; Moules
B30B 15/34 - Chauffage ou refroidissement des presses ou des parties de presse
C22C 1/05 - Mélanges de poudre métallique et de poudre non métallique
C22C 47/14 - Fabrication d'alliages contenant des fibres ou des filaments métalliques ou non métalliques par métallurgie des poudres, c. à d. par traitement de mélanges de poudre métallique et de fibres ou de filaments
C22C 49/02 - Alliages contenant des fibres ou des filaments métalliques ou non métalliques caractérisés par le matériau de la matrice
C22C 49/14 - Alliages contenant des fibres ou des filaments métalliques ou non métalliques caractérisés par les fibres ou les filaments
5.
NEW N-HETEROARYLBENZAMIDES DERIVATIVES AS FLT3 INHIBITORS
INSERM (INSTITUT NATIONAL DE LA SANTÉ ET DE LA RECHERCHE MÉDICALE) (France)
CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (France)
UNIVERSITE DE MONTPELLIER (France)
UNIVERSITE DE STRASBOURG (France)
Inventeur(s)
Mornat, Pauline
Sokoloff, Pierre
Rognan, Didier
Abrégé
48481436141414142214141414141414144)alkoxy group. The present invention further related to a pharmaceutical composition comprising it and to its use in the prevention and/or the treatment of pain.
C07D 217/02 - Composés hétérocycliques contenant les systèmes cycliques de l'isoquinoléine ou de l'isoquinoléine hydrogénée avec uniquement des atomes d'hydrogène ou des radicaux ne contenant que des atomes d'hydrogène et de carbone, liés directement aux atomes de carbone du cycle contenant l'azote; Alkylène-bis-isoquinoléines
C07D 241/42 - Benzopyrazines avec uniquement des atomes d'hydrogène, des radicaux hydrocarbonés ou des radicaux hydrocarbonés substitués, liés directement aux atomes de carbone de l'hétérocycle
C07D 401/12 - Composés hétérocycliques contenant plusieurs hétérocycles comportant des atomes d'azote comme uniques hétéro-atomes du cycle, au moins un cycle étant un cycle à six chaînons avec un unique atome d'azote contenant deux hétérocycles liés par une chaîne contenant des hétéro-atomes comme chaînons
A61P 29/00 - Agents analgésiques, antipyrétiques ou anti-inflammatoires non centraux, p.ex. agents antirhumatismaux; Médicaments anti-inflammatoires non stéroïdiens [AINS]
A61K 31/4709 - Quinoléines non condensées contenant d'autres hétérocycles
A61K 31/4725 - Isoquinoléines non condensées, p.ex. papavérine contenant d'autres hétérocycles
A61K 31/498 - Pyrazines ou pipérazines condensées en ortho ou en péri avec des systèmes carbocycliques, p.ex. quinoxaline, phénazine
A61K 31/502 - Pyridazines; Pyridazines hydrogénées condensées en ortho ou en péri avec des systèmes carbocycliques, p.ex. cinnoline, phtalazine
6.
METHODS AND PHARMACEUTICAL COMPOSITION FOR THE TREATMENT OF ALPHA-SYNUCLEINOPATHIES
INSTITUT NATIONAL DE LA SANTÉ ET DE LA RECHERCHE MÉDICALE (France)
ASSISTANCE PUBLIQUE-HÔPITAUX DE PARIS (APHP) (France)
CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (France)
ICM (INSTITUT DU CERVEAU ET DE LA MOELLE EPINIÈRE) (France)
SORBONNE UNIVERSITÉ (France)
OSAKA UNIVERSITY (Japon)
Inventeur(s)
Cartier-Lacave, Nathalie
Besnard-Guerin, Corinne
Rousselot, Lisa
Mochizuki, Hideki
Tada, Satoru
Abrégé
The present invention relates to the treatment alpha-synucleinopathies. In this study, the inventors showed that restoring brain cholesterol pathway and defective autophagy by AAV- CYP46A1 delivery, as evidenced in several neurodegenerative pathologies, could be a relevant therapeutic approach in alpha-synucleinopathies and particularly in PD. Thus the present invention relates to a vector for use in the treatment of alpha-synucleinopathies, which vector comprises the full sequence of cholesterol 24-hydroxylase encoding nucleic acid.
A61P 25/28 - Médicaments pour le traitement des troubles du système nerveux des troubles dégénératifs du système nerveux central, p.ex. agents nootropes, activateurs de la cognition, médicaments pour traiter la maladie d'Alzheimer ou d'autres formes de démence
CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (France)
UNIVERSITE DE LILLE (France)
NANTES UNIVERSITÉ (France)
UNIVERSITE POLYTECHNIQUE HAUTS-DE-FRANCE (France)
CENTRALE LILLE INSTITUT (France)
Inventeur(s)
Hallot, Maxime
Robert, Kévin
Marlec, Florent
Asbani, Bouchra
Lethien, Christophe
Roussel, Pascal
Bounor, Botayna
Abrégé
A microstructured substrate comprising a main body and a plurality of elongated elementary microstructures extending from the main body, wherein the microstructured substrate comprises a plurality of nanowires positioned on at least one area of the surface of the main body and on the surface of the elementary microstructures that extend from the main body over said area.
H01G 11/26 - Condensateurs hybrides, c. à d. ayant des électrodes positive et négative différentes; Condensateurs électriques à double couche [EDL]; Procédés de fabrication desdits condensateurs ou de leurs composants Électrodes caractérisées par leur structure, p.ex. multicouches, selon la porosité ou les caractéristiques de surface
H01G 11/28 - Condensateurs hybrides, c. à d. ayant des électrodes positive et négative différentes; Condensateurs électriques à double couche [EDL]; Procédés de fabrication desdits condensateurs ou de leurs composants Électrodes caractérisées par leur structure, p.ex. multicouches, selon la porosité ou les caractéristiques de surface agencées ou disposées sur un collecteur de courant; Couches ou phases entre les électrodes et les collecteurs de courant, p.ex. adhésifs
H01M 4/1391 - Procédés de fabrication d'électrodes à base d'oxydes ou d'hydroxydes mixtes, ou de mélanges d'oxydes ou d'hydroxydes, p.ex. LiCoOx
H01M 4/505 - Emploi de substances spécifiées comme matériaux actifs, masses actives, liquides actifs d'oxydes ou d'hydroxydes inorganiques de manganèse d'oxydes ou d'hydroxydes mixtes contenant du manganèse pour insérer ou intercaler des métaux légers, p.ex. LiMn2O4 ou LiMn2OxFy
H01M 4/525 - Emploi de substances spécifiées comme matériaux actifs, masses actives, liquides actifs d'oxydes ou d'hydroxydes inorganiques de nickel, de cobalt ou de fer d'oxydes ou d'hydroxydes mixtes contenant du fer, du cobalt ou du nickel pour insérer ou intercaler des métaux légers, p.ex. LiNiO2, LiCoO2 ou LiCoOxFy
H01M 4/134 - PROCÉDÉS OU MOYENS POUR LA CONVERSION DIRECTE DE L'ÉNERGIE CHIMIQUE EN ÉNERGIE ÉLECTRIQUE, p.ex. BATTERIES Électrodes Électrodes composées d'un ou comprenant un matériau actif Électrodes pour accumulateurs à électrolyte non aqueux, p.ex. pour accumulateurs au lithium; Leurs procédés de fabrication Électrodes à base de métaux, de Si ou d'alliages
Centre national de la recherche scientifique (France)
Université de Strasbourg (France)
Universidade Federal do Rio de Janeiro (Brésil)
Inventeur(s)
Louis, Benoit
Bingre, Rogeria
Megias Sayago, Cristina
Maciel Pereira, Marcelo
Gomes Flores, Camila
Abrégé
The present invention relates to a process for preparing a zeolite ZSM-5 presenting a Si/Al molar ratio comprised between 2 and 8, preferably between 3 and 8, comprising the following steps: a) mixing at least one silicon source, at least one aluminum source, at least one organic template and at least one aqueous solvent, in order to obtain a synthesis mixture in solution or gel form; b) ageing the mixture obtained in step a) at a temperature of between 20° C. and 200° C. during at least 30 minutes; and d) crystallizing the resulting mixture during at least 24 hours, wherein a step c) of adding wood lignin or oxidized wood lignin to the mixture is performed after step a) or after step b). It also relates to a zeolite which is obtainable by such a process, and to its use.
C07C 1/24 - Préparation d'hydrocarbures à partir d'un ou plusieurs composés, aucun d'eux n'étant un hydrocarbure à partir de composés organiques ne renfermant que des atomes d'oxygène en tant qu'hétéro-atomes par élimination d'eau
CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (CNRS) (France)
ECOLE NATIONALE SUPÉRIEURE D'INGÉNIEURS DE CAEN (France)
Inventeur(s)
Mouaddib, Abdel-Ilah
Jeanpierre, Laurent
Abrégé
A system and a method for generating a navigation path for an autonomous system. The method comprises receiving data comprising characteristics of entities, the entities defining an environment in which the autonomous system is configured to operate; receiving first instructions causing the autonomous system to identify a destination in the environment; generating a navigation path comprising waypoints to be followed by the autonomous system to reach the destination, the waypoints being generated based on the characteristics of the entities and defining segmental paths; executing second instructions causing the autonomous system to navigate along the navigation path; and upon navigating from a first waypoint to a second waypoint: accessing updates of the characteristics of the entities located in a vicinity of a corresponding segmental path; generating a sub-path between the first waypoint and the second waypoint based on second information; and navigating along the sub-path to reach the second waypoint.
CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (France)
UNIVERSITE DE RENNES (France)
NANTES UNIVERSITE (France)
CENTRALESUPELEC (France)
INSA DE RENNES (France)
Inventeur(s)
Fraysse, Jean-Philippe
Lassauce, Léonin
Tubau, Ségolène
Ettorre, Mauro
Legay, Hervé
Abrégé
A quasi-optical beamformer includes a plurality N> 1 of power feeds (PF), each of the i∈[1; N] power feeds (PF) being configured to emit a respective radio-frequency beam denoted Ri, a radio-frequency transmission line (LT) fed at a first end by the power feeds and comprising at a second end a plurality of network ports (PR) that are configured to collect radio-frequency radiation, the transmission line (LT) comprising a radio-frequency waveguide (GO) that comprises at least two metal plates (PM) that are stacked so as to guide the radio-frequency beams Ri, i∈[1; N] towards the network ports (PR), the transmission line (LT) extending along a central main axis denoted axis x, a first reflector (M1) having a first centre (C1) centred on the axis x and a first effective radius of curvature and being configured to reflect the guided radio-frequency beams Ri, i∈[1; N], a second reflector (M2) having a second effective radius of curvature and being configured to reflect the radio-frequency beams (RFi) reflected by the first reflector so as to direct them towards the network ports so as to form output radio-frequency beams (RSi), the first and second effective radii of curvature and an arrangement of the power feeds (PF) with respect to the first reflector being configured so that: each of the output radio-frequency beams (RSi) is a plane wave, and a transverse amplitude distribution Ai, on the network ports (PR), of each output radio-frequency beam (RSi), is substantially identical.
H01Q 19/06 - Combinaisons d'éléments actifs primaires d'antennes avec des dispositifs secondaires, p.ex. avec des dispositifs quasi optiques, pour donner à une antenne une caractéristique directionnelle désirée utilisant des dispositifs de réfraction ou de diffraction, p.ex. lentilles
H01Q 23/00 - Antennes comportant des circuits ou des éléments de circuit actifs qui leur sont intégrés ou liés
H04B 7/06 - Systèmes de diversité; Systèmes à plusieurs antennes, c. à d. émission ou réception utilisant plusieurs antennes utilisant plusieurs antennes indépendantes espacées à la station d'émission
11.
PRODUCTION OF A LIQUID ORGANIC ELECTROLYTE METAL-ION BATTERY COMPONENT, AND ELECTROCHEMICAL CELL COMPRISING SUCH A COMPONENT
CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (France)
UNIVERSITE AMIENS PICARDIE JULES VERNE (France)
UNIVERSITE DE LILLE (France)
ECOLE NATIONALE SUPERIEURE DES ARTS ET INDUSTRIES TEXTILES (France)
Inventeur(s)
Maurel, Alexis
Grugeon, Sylvie
Dupont, Loïc
Panier, Stéphane
Cayla, Aurélie
Gomes, Luisa Larissa Arnaldo
Boudeville, Victor
Abrégé
The subject matter of the present invention is a method for producing such components, the components that can be obtained by this method and the use of these components in the production of a liquid organic electrolyte electrochemical cell.
H01M 4/62 - Emploi de substances spécifiées inactives comme ingrédients pour les masses actives, p.ex. liants, charges
H01M 10/0525 - Batteries du type "rocking chair" ou "fauteuil à bascule", p.ex. batteries à insertion ou intercalation de lithium dans les deux électrodes; Batteries à l'ion lithium
H01M 50/414 - Résines synthétiques, p.ex. thermoplastiques ou thermodurcissables
H01M 50/446 - Matériau composite constitué d’un mélange de matériaux organiques et inorganiques
12.
CATALYST SYSTEM BASED ON AN IRON COMPLEX AND USE THEREOF FOR THE POLYMERIZATION OF CONJUGATED DIENES
COMPAGNIE GENERALE DES ETABLISSEMENTS MICHELIN (France)
CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (France)
ECOLE SUPÉRIEURE DE CHIMIE PHYSIQUE ELECTRONIQUE DE LYON (France)
INSTITUT NATIONAL DES SCIENCES APPLIQUÉES DE LYON (France)
UNIVERSITE CLAUDE BERNARD LYON 1 (France)
Inventeur(s)
Vaultier, Florent
Hall, Nicolas
Monteil, Vincent
Raynaud, Jean
Abrégé
22120320620312032062020 aromatic radical, which may be substituted or unsubstituted; for the polymerization of conjugated dienes, in particular the stereospecific polymerization of 1,3-dienes, especially butadiene and isoprene.
C08F 4/70 - Métaux du groupe du fer, métaux du groupe du platine ou leurs composés
C08F 136/04 - Homopolymères de composés possédant un ou plusieurs radicaux aliphatiques non saturés, l'un au moins contenant plusieurs liaisons doubles carbone-carbone le radical ne contenant que deux doubles liaisons carbone-carbone conjuguées
13.
METHOD FOR MEASURING AND PROCESSING OF THERMOGRAPHY DATA
CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (France)
UNIVERSITE DE RENNES (France)
NANTES UNIVERSITE (France)
CENTRALESUPELEC (France)
INSA DE RENNES (France)
Inventeur(s)
Fraysse, Jean-Philippe
Lassauce, Leonin
Tubau, Segolene
Ettorre, Mauro
Legay, Herve
Abrégé
Quasi-optical beamformer (1) comprising. -a plurality N > 1 of powei feeds (PF), each of the i c [1;N] power feeds (PF) being configured to emit a respective radio-frequency beam denoted Ri, - a radio-frequency transmission line (LT) fed at a first end by the power feeds and comprising at a second end a plurality of network ports (PR) that are configured to collect radio-frequency radiation, the transmission line (LT) comprising a radio-frequency waveguide (GO) that comprises at least two metal plates (PM) that are stacked so as to guide the radio-frequency beams Ri, i c [1; IV] towards the network ports (PR), the lransmission line (LT) extending along a cenlral main axis denoted axis x, - a first reflector (M1) having a first centre (C1) centred on the axis x and a first effective radius of curvature and being configured to reflect the guided radio-frequency beams Roi c [1; N], - a second reflector (M2) having a second effective radius of curvature and being configured to reflect the radio-frequency beams (RF) reflected by the first reflector so as to direct them towards the network ports so as to form output radio-frequency beams (RSi), the first and second effective radii of curvature and an arrangement of the power feeds (PF) with respect to the first reflector being configured so that - each of the output radio-frequency beams (RS,) is a plane wave, and - a transverse amplitude distribution Ai, on the network ports (PR), of each output radio-frequency beam (RS), is substantially identical
H01Q 19/17 - Combinaisons d'éléments actifs primaires d'antennes avec des dispositifs secondaires, p.ex. avec des dispositifs quasi optiques, pour donner à une antenne une caractéristique directionnelle désirée utilisant des surfaces réfléchissantes où les surfaces sont concaves la source rayonnante primaire comprenant plusieurs éléments rayonnants
Centre National de la Recherche Scientifique (CNRS) (France)
Sorbonne Universite (France)
Institut National de la Santé et de la Recherche Médicale (INSERM) (France)
Université Claude Bernard Lyon 1 (France)
Universite de Rennes 1 (France)
Inventeur(s)
Bach, Stéphane
Comte, Arnaud
Delehouze, Claire
Dimanche-Boitrel, Marie-Thérèse
Goekjian, Peter
Abrégé
The present invention relates to a compound of the following general formula (I) or a pharmaceutically acceptable salt and/or solvate thereof, for use as drug for inhibiting ferroptosis.
The present invention relates to a compound of the following general formula (I) or a pharmaceutically acceptable salt and/or solvate thereof, for use as drug for inhibiting ferroptosis.
A61K 31/437 - Composés hétérocycliques ayant l'azote comme hétéro-atome d'un cycle, p.ex. guanéthidine ou rifamycines ayant des cycles à six chaînons avec un azote comme seul hétéro-atome d'un cycle condensés en ortho ou en péri avec des systèmes hétérocycliques le système hétérocyclique contenant un cycle à cinq chaînons ayant l'azote comme hétéro-atome du cycle, p.ex. indolizine, bêta-carboline
A61K 31/444 - Pyridines non condensées; Leurs dérivés hydrogénés contenant d'autres systèmes hétérocycliques contenant un cycle à six chaînons avec l'azote comme hétéro-atome du cycle, p.ex. amrinone
A61K 31/4545 - Pipéridines non condensées, p.ex. pipérocaïne contenant d'autres systèmes hétérocycliques contenant un cycle à six chaînons avec l'azote comme hétéro-atome du cycle, p.ex. pipampérone, anabasine
A61K 31/496 - Pipérazines non condensées contenant d'autres hétérocycles, p.ex. rifampine, thiothixène
A61K 31/5377 - 1,4-Oxazines, p.ex. morpholine non condensées et contenant d'autres hétérocycles, p.ex. timolol
INSTITUT NATIONAL DE LA SANTÉ ET DE LA RECHERCHE MÉDICALE (France)
CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (CNRS) (France)
UNIVERSITÉ DE MONTPELLIER (France)
Inventeur(s)
Bonnet, Jérôme
Abrégé
Bile salts are steroid acids derived from cholesterol in the liver, are released into the gastrointestinal tract to aid in digestion and are thoroughly modified by the resident gut microbiota. Bile acids act as versatile signaling molecules with a variety In of endocrine functions and are linked to several diseases. In particular, serum and urinary bile salts represent biomarkers for early diagnostics of liver dysfunction, yet their current detection methods are impractical and hard to scale. Here the inventors engineered engineered synthetic bile salt receptors using VtrA as sensing domains connected to E. coli CadC system which activates transcription upon dimerization. The performance of the system was assayed for various selection of promoters and they can show that fine tunable response that may be reached by changing expression levels of the bile salt receptor. By performing multiple rounds of directed evolution of the VtrA sensor the inventors obtained a collection of variants with a lower limit of detection and a higher sensitivity. Finally, they show that their bactosensor can detect pathological bile-salt concentrations in samples from patients with liver dysfunction. The present invention thus relates to bile salts bactosensor and use thereof for diagnostic and therapeutic purposes.
C07K 14/195 - Peptides ayant plus de 20 amino-acides; Gastrines; Somatostatines; Mélanotropines; Leurs dérivés provenant de bactéries
C12N 15/70 - Vecteurs ou systèmes d'expression spécialement adaptés à E. coli
G01N 33/68 - Analyse chimique de matériau biologique, p.ex. de sang ou d'urine; Test par des méthodes faisant intervenir la formation de liaisons biospécifiques par ligands; Test immunologique faisant intervenir des protéines, peptides ou amino-acides
17.
ANTIBODIES HAVING SPECIFICITY FOR BTN2 AND USES THEREOF
C07K 16/28 - Immunoglobulines, p.ex. anticorps monoclonaux ou polyclonaux contre du matériel provenant d'animaux ou d'humains contre des récepteurs, des antigènes de surface cellulaire ou des déterminants de surface cellulaire
Institut National de la Santé et de la Recherche Médicale (France)
Universite de Bretagne Occidentale (France)
Ecole Nationale Superieure de Chimie de Rennes (France)
Institut National des Sciences Appliquees de Rennes (France)
Universite Nangui Abrogoua (Côte d’Ivoire)
Centre National de la Recherche Scientifique (France)
Universite de Rennes 1 (France)
Inventeur(s)
Bazureau, Jean Pierre
Dago, Déliko Camille
Voli, Lou Anna
Mignen, Olivier
Brigaudeau, Christophe
Berko, Yves-Alain
Abrégé
The present invention provides SOCE inhibitors that are useful as therapeutic agents in a variety of applications. The present invention also relates to pharmaceutical compositions, products and kits comprising such SOCE inhibitors, and methods of using the SOCE inhibitors in the treatment of a variety of diseases.
A61P 29/00 - Agents analgésiques, antipyrétiques ou anti-inflammatoires non centraux, p.ex. agents antirhumatismaux; Médicaments anti-inflammatoires non stéroïdiens [AINS]
20.
METHOD FOR SERVOCONTROLLING AN OPTICAL DEVICE COMPRISING A LASER AND A CAVITY, MAKING IT POSSIBLE TO COMPENSATE FOR AN AMPLITUDE MODULATION INTRODUCED BY A PHASE MODULATOR
CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (France)
Inventeur(s)
Feugnet, Gilles
Descampeaux, Maxime
Bretenaker, Fabien
Abrégé
A method for the servo control of an optical device includes a cavity exhibiting resonance around a center frequency ƒc, a laser and a phase modulator, the method being designed to servo-control the cavity to the laser or vice versa and to compensate for an amplitude modulation introduced by the phase modulator, the method comprising, inter alia, the following steps: A. varying a difference δν between the optical frequency of the laser radiation and the center frequency, such that the optical frequency scans the resonance, the difference being controlled by a parameter of an element of the device, and for each difference δνi i. modulating, at a modulation frequency ƒmod, a phase of the laser radiation, through a modulation phase ϕmod, with the phase modulator, ii. injecting the phase-modulated radiation into the cavity, iii. using a photodiode to detect radiation reflected or transmitted by the cavity and generating an electrical signal (St, Sr) representative of the intensity of the detected radiation, iv. demodulating the electrical signal at the modulation frequency ƒmod by synchronously generating a first demodulated signal and a second demodulated signal representative of the demodulated electrical signal, respectively at a first demodulation phase ϕdem,1 and at a second modulation phase ϕdem,2ϕdem,2≈ϕdem,1k, where k∈[0; 2π] is different from the first phase, and by filtering the first and the second signal so as to retain only a DC component of the first demodulated signal Vϵ1, called error signal 1, and of the second demodulated signal Vϵ2, called error signal 2.
H01S 3/00 - Lasers, c. à d. dispositifs utilisant l'émission stimulée de rayonnement électromagnétique dans la gamme de l’infrarouge, du visible ou de l’ultraviolet
H01S 3/137 - Stabilisation de paramètres de sortie de laser, p.ex. fréquence ou amplitude par commande de dispositifs placés dans la cavité pour la stabilisation de la fréquence
H01S 3/139 - Stabilisation de paramètres de sortie de laser, p.ex. fréquence ou amplitude par commande de la position relative ou des propriétés réfléchissantes des réflecteurs de la cavité
21.
USE OF INHIBITORS OF THE HIPPO SIGNALLING PATHWAY FOR THE TREATMENT OF CHRONIC NEPHROPATHIES
INSTITUT NATIONAL DE LA SANTÉ ET DE LA RECHERCHE MÉDICALE (France)
ASSISTANCE PUBLIQUE-HÔPITAUX DE PARIS (APHP) (France)
CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (France)
FONDATION IMAGINE (France)
UNIVERSITÉ PARIS CITÉ (France)
Inventeur(s)
Viau, Amandine
Bienaime, Frank
Ferri, Giulia
Saunier, Sophie
Abrégé
Chronic nephropathies, in particular tubulointertial nephropathy or tubulointertial nephropathy with fibrosis feature represent a real global public health concern. In particular, nephronophthisis (NPH) is an orphan genetic disease affecting the kidney. This recessive affection usually manifests with polyuria followed by a gradual reduction in kidney function related to progressive renal scarring. To date, no treatment is available for this affection. Now the inventors show that inhibition of the Hippo signalling pathway represents a new therapeutic avenue for the treatment of chronic nephropathies such as NPH. In particular, the inventors show that inhibition of MST1/2 or LATS1/2 reduces the NPH pro-inflammatory signature in mIMCD-3 renal cells even in response to uropathogenic bacteria. Thus the present invention relates to use of inhibitors of the Hippo signalling pathway for the treatment of chronic nephropathies.
A61K 31/551 - Composés hétérocycliques ayant l'azote comme hétéro-atome d'un cycle, p.ex. guanéthidine ou rifamycines ayant des cycles à sept chaînons, p.ex. azélastine, pentylènetétrazole ayant deux atomes d'azote comme hétéro-atomes d'un cycle, p.ex. clozapine, dilazèpe
A61K 31/437 - Composés hétérocycliques ayant l'azote comme hétéro-atome d'un cycle, p.ex. guanéthidine ou rifamycines ayant des cycles à six chaînons avec un azote comme seul hétéro-atome d'un cycle condensés en ortho ou en péri avec des systèmes hétérocycliques le système hétérocyclique contenant un cycle à cinq chaînons ayant l'azote comme hétéro-atome du cycle, p.ex. indolizine, bêta-carboline
A61P 1/16 - Médicaments pour le traitement des troubles du tractus alimentaire ou de l'appareil digestif des troubles de la vésicule biliaire ou du foie, p.ex. protecteurs hépatiques, cholagogues, cholélitholytiques
22.
PROCESS FOR THE FLUORINATION AND/OR CYCLIZATION OF AN AMINO ALKENE OR ALKYNE IN A CONTINUOUS STREAM AND FACILITY FOR PERFORMING THE PROCESS
CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (France)
SORBONNE UNIVERSITE (France)
Inventeur(s)
Abada, Zahra
Martin-Mingot, Agnès
Bleriot, Yves
Thibaudeau, Sébastien
Abou-Hassan, Ali
Abrégé
The present invention relates to a process for the fluorination and/or cyclization of an amino alkene or alkyne in a continuous-stream microreactor. The invention also relates to a facility for performing such a process.
C07D 209/08 - Indoles; Indoles hydrogénés avec uniquement des atomes d'hydrogène ou des radicaux ne contenant que des atomes d'hydrogène et de carbone, liés directement aux atomes de carbone de l'hétérocycle
C07C 311/00 - Amides d'acides sulfoniques, c. à d. composés comportant des atomes d'oxygène, liés par des liaisons simples, de groupes sulfoniques remplacés par des atomes d'azote, ne faisant pas partie de groupes nitro ou nitroso
C07D 211/14 - Composés hétérocycliques contenant des cycles pyridiques hydrogénés, non condensés avec d'autres cycles avec uniquement des atomes d'hydrogène et de carbone liés directement à l'atome d'azote du cycle ne comportant pas de liaison double entre chaînons cycliques ou entre chaînons cycliques et chaînons non cycliques avec des radicaux hydrocarbonés ou des radicaux hydrocarbonés substitués, liés directement aux atomes de carbone du cycle avec des radicaux ne contenant que des atomes de carbone et d'hydrogène liés aux atomes de carbone du cycle avec des radicaux hydrocarbonés ou des radicaux hydrocarbonés substitués, liés à l'atome d'azote du cycle
C07D 211/38 - Atomes d'halogènes ou radicaux nitro
C07D 215/06 - Composés hétérocycliques contenant les systèmes cycliques de la quinoléine ou de la quinoléine hydrogénée ne comportant pas de liaison entre l'atome d'azote du cycle et un chaînon non cyclique ou ne comportant que des atomes d'hydrogène ou de carbone liés directement à l'atome d'azote du cycle avec uniquement des atomes d'hydrogène ou des radicaux ne contenant que des atomes d'hydrogène et de carbone, liés directement aux atomes de carbone du cycle comportant uniquement des atomes d'hydrogène, des radicaux hydrocarbonés ou des radicaux hydrocarbonés substitués, liés à l'atome d'azote du cycle
C07D 519/04 - Alcaloïdes de dimères d'indole, p.ex. vincaleucoblastine
C07D 213/12 - Préparation par cyclisation utilisant de l'ammoniac, des amines, des sels d'amines ou des nitriles à partir de composés non saturés
C07C 209/74 - Préparation de composés contenant des groupes amino liés à un squelette carboné à partir d'amines, par des réactions n'impliquant pas de groupes amino, p.ex. réduction d'amines non saturées, aromatisation ou substitution du squelette carboné par halogénation, halogénhydratation, déshalogénation ou déshalogénhydratation
C07C 303/40 - Préparation d'esters ou d'amides d'acides sulfuriques; Préparation d'acides sulfoniques ou de leurs esters, halogénures, anhydrides ou amides d'amides d'acides sulfoniques par des réactions n'impliquant pas la formation de groupes sulfonamide
23.
HYBRID SOLID ELECTROLYTE WITH REDUCED POLYMER/CERAMIC INTERFACIAL STRENGTH
CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (France)
UNIVERSITÉ SAVOIE MONT BLANC (France)
Inventeur(s)
Pavlenko, Ekaterina
Jordy, Christian
Bouchet, Renaud
Mangani, Léa
Isaac, James
Devaux, Didier
Abrégé
The present application relates to ceramic/polymer hybrid solid electrolytes with improved interfacial strength, comprising a surface-dehydrated pre-treated ceramic.
H01M 10/056 - Accumulateurs à électrolyte non aqueux caractérisés par les matériaux utilisés comme électrolytes, p.ex. électrolytes mixtes inorganiques/organiques
H01M 6/18 - PROCÉDÉS OU MOYENS POUR LA CONVERSION DIRECTE DE L'ÉNERGIE CHIMIQUE EN ÉNERGIE ÉLECTRIQUE, p.ex. BATTERIES Éléments primaires; Leur fabrication Éléments avec électrolytes non aqueux avec électrolyte solide
CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (France)
Inventeur(s)
Annereau, Maxime
Dowek, Antoine
Legrand, François-Xavier
Rieutord, André
Abrégé
The invention provides a pharmaceutical composition in oral liquid form, comprising vinorelbine, or a pharmaceutically acceptable salt thereof, and a cyclodextrin that is sulfobutylether-beta-cyclodextrin (SBE-beta-CD), preferably wherein at least 95%, vinorelbine, or said pharmaceutically acceptable salt thereof, is in form of an inclusion complex with said cyclodextrin.
A61K 47/69 - Préparations médicinales caractérisées par les ingrédients non actifs utilisés, p.ex. les supports ou les additifs inertes; Agents de ciblage ou de modification chimiquement liés à l’ingrédient actif l’ingrédient non actif étant chimiquement lié à l’ingrédient actif, p.ex. conjugués polymère-médicament le conjugué étant caractérisé par sa forme physique ou sa forme galénique, p.ex. émulsion, particule, complexe d’inclusion, stent ou kit
INSTITUT NATIONAL DE LA SANTÉ ET DE LA RECHERCHE MÉDICALE (France)
UNIVERSITÉ PARIS CITÉ (France)
CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (France)
Inventeur(s)
Pendino, Frédéric
Donnadieu, Emmanuel
Fumagalli, Mattia
An, Dongjie
Abrégé
The present invention relates to the adoptive therapy using notably CAR-T cells. Here the inventors used a lentiviral vector approach to silence RINF expression in a shRNA- dependent manner and evaluate the consequences of RINF silencing on human CAR-T cells proliferation ex vivo and their functionality and capacity to eradicate tumor cells in vivo. More, the proposed methodology to improve CAR-T cells persistence and efficacy by disrupting RINF/CXXC5 is not restricted to patients suffering from hematological or solid cancers (anti- CD19, anti-EGFR, anti-BCMA…) but could be also used to improve the efficacy of ACT in non-cancer diseases by such as lupus (1), cardiac fibrosis (2) or aging related-disorders (3). Thus, the present invention relates to an immune cell characterized in that it is defective for RINF.
CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (France)
UNIVERSITE DE MONTPELLIER (France)
ECOLE NATIONALE SUPERIEURE DE CHIMIE DE MONTPELLIER (France)
Inventeur(s)
Delavarde, Aliénor
Maillard, Sylvain
Caillol, Sylvain
Pinaud, Julien
Abrégé
The invention primarily relates to a biobased polyurethane resin composition, characterised in that it is obtained by mixing a volume V1 of polyisocyanate phase and a volume V2 of polyol phase, and in that: - either the polyisocyanate phase includes at least two polyisocyanates, at least one of which is an isocyanate-terminated prepolymer that comprises at least 70% biobased carbons and the other comprises at least 60% biobased carbons, and the polyol phase includes at least one polyol that comprises at least 80% biobased carbons, - or the polyol phase includes at least two polyols that each comprise at least 80% biobased carbons, and the polyisocyanate phase includes at least one isocyanate-terminated prepolymer that comprises at least 70% biobased carbons. Preferentially, the number of isocyanate functions in the polyisocyanate phase is equal to the number of alcohol functions in the polyol phase. The invention also relates to a method for manufacturing such a composition, which method advantageously involves evaluating the equivalent reactive volumes of each compound. The invention lastly relates to a printed support at least partially covered with a dome of resin, which dome of resin is produced from said polyurethane resin composition.
C08G 18/10 - Procédés mettant en œuvre un prépolymère impliquant la réaction d'isocyanates ou d'isothiocyanates avec des composés contenant des hydrogènes actifs, dans une première étape réactionnelle
C08G 18/72 - Polyisocyanates ou polyisothiocyanates
C08G 18/79 - Polyisocyanates ou polyisothiocyanates contenant des hétéro-atomes autres que l'azote, l'oxygène ou le soufre de l'isocyanate ou de l'isothiocyanate de l'azote caractérisés par le polyisocyanate utilisé, celui-ci contenant des groupes formés par oligomérisation d'isocyanates ou d'isothiocyanates
COMMISSARIAT A L'ENERGIE ATOMIQUE ET AUX ENERGIES ALTERNATIVES (France)
CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (France)
UNIVERSITE DE MONTPELLIER (France)
ECOLE NATIONALE SUPÉRIEURE DE CHIMIE DE MONTPELLIER (France)
Inventeur(s)
Pellet-Rostaing, Stéphane
Giusti, Fabrice
Arrachart, Guilhem
Piton, Raphaëlle
Baus-Lagarde, Béatrice
Abrégé
The invention relates to the use of a lipophilic derivative of an aminopolycarboxylic acid as an extractant to extract at least one rare earth from an acidic aqueous solution. Applications: production of rare earths from concentrates derived from urban ores and, in particular, from concentrates from waste electrical and electronic equipment such as used or discarded NdFeB permanent magnets; production of rare earths from concentrates derived from natural ores or from concentrates derived from residues of natural ores.
C22B 3/26 - Traitement ou purification de solutions, p.ex. de solutions obtenues par lixiviation par extraction liquide-liquide utilisant des composés organiques
C22B 7/00 - Mise en œuvre de matériaux autres que des minerais, p.ex. des rognures, pour produire des métaux non ferreux ou leurs composés
C07C 237/06 - Amides d'acides carboxyliques, le squelette carboné de la partie acide étant substitué de plus par des groupes amino ayant les atomes de carbone des groupes carboxamide liés à des atomes de carbone acycliques du squelette carboné le squelette carboné étant acyclique et saturé ayant les atomes d'azote des groupes carboxamide liés à des atomes d'hydrogène ou à des atomes de carbone acycliques
28.
CRYSTALLINE HAFNIUM OXIDE NANOPARTICLES, METHOD FOR MANUFACTURING SAME, AND USES THEREOF
CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (France)
INSERM (INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE) (France)
ECOLE NORMALE SUPERIEURE DE LYON (France)
UNIVERSITE GRENOBLE ALPES (France)
Inventeur(s)
Chaput, Frederic
Lerouge, Frederic
Karpati, Szilvia
Bulin, Anne-Laure
Abrégé
Disclosed are crystalline hafnium oxide nanoparticles, a method for manufacturing same, and the uses thereof. The invention relates to crystalline hafnium oxide nanoparticles, characterized in that they bear amide molecules and/or at least one amide degradation product chosen from a carboxylic acid, an amine or an amino acid and/or residues of said molecules on their surface.
COMPAGNIE GENERALE DES ETABLISSEMENTS MICHELIN (France)
CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (France)
ECOLE SUPÉRIEURE DE CHIMIE PHYSIQUE ELECTRONIQUE DE LYON (France)
UNIVERSITÉ CLAUDE BERNARD LYON 1 (France)
Inventeur(s)
Ngo, Robert
Baulu, Nicolas
Boisson, Christophe
D'Agosto, Franck
Jean-Baptiste-Dit-Dominique, François
Thuilliez, Julien
Abrégé
A catalytic system based on at least one rare-earth metallocene and an organomagnesium reagent as co-catalyst of formula RB—(Mg—RA)m—Mg—RB is provided. According to the formula, RB comprises a benzene nucleus substituted with the magnesium atom. One of the carbon atoms of the benzene nucleus ortho to the magnesium is substituted with a methyl, an ethyl or an isopropyl or forms a ring with the carbon atom which is its closest neighbour and which is meta to the magnesium. The other carbon atom of the benzene nucleus ortho to the magnesium is substituted with a methyl, an ethyl or an isopropyl. RA is a divalent aliphatic hydrocarbon-based chain, optionally interrupted with one or more oxygen or sulfur atoms or with one or more arylene groups. The m is a number greater than or equal to 1, preferably 1. The catalytic system allows the synthesis of dienic and/or ethylenic telechelic polymers.
C08F 4/54 - Métaux; Hydrures métalliques; Composés organiques de métal; Leur utilisation comme précurseurs de catalyseurs choisis parmi les métaux légers, le zinc, le cadmium, le mercure, le cuivre, l'argent, l'or, le bore, le gallium, l'indium, le thallium, les terres rares ou les actinides en mélange avec d'autres de leurs composés
CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (France)
UNIVERSITÉ DE PARIS CITÉ (France)
YSLAB (France)
Inventeur(s)
Rat, Patrice
Olivier, Elodie
Dutot, Melody
Wakx, Anaïs
Abrégé
The invention relates to a cell culture comprising a placental cell and a culture medium consisting of minimal essential nutriments and a low amount of serum. The invention also relates to a method using the cell culture for identifying endocrine disruptor.
G01N 33/50 - Analyse chimique de matériau biologique, p.ex. de sang ou d'urine; Test par des méthodes faisant intervenir la formation de liaisons biospécifiques par ligands; Test immunologique
C12N 5/073 - Cellules ou tissus embryonnaires; Cellules fœtales ou tissus fœtaux
G01N 33/74 - Analyse chimique de matériau biologique, p.ex. de sang ou d'urine; Test par des méthodes faisant intervenir la formation de liaisons biospécifiques par ligands; Test immunologique faisant intervenir des hormones
31.
METHOD FOR RECOGNIZING A PATTERN IN AN IMAGE AND ASSOCIATED DEVICES
CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (France)
UNIVERSITE DE MONTPELLIER (France)
Inventeur(s)
Todri-Sanial, Aida
Abrégé
A method for recognizing a pattern in an image including a training phase of an oscillatory neuron network, the oscillatory neuron network being adapted to output a pattern when an image is inputted, the oscillatory neuron network being implemented by a circuitry comprising oscillators linked by interconnections including at least one coupling resistance having a coupling resistance value, the oscillators being coupled by a sub-harmonic injection technique and coding the output by their relative phase difference, the coupling resistance values being learnt during the training phase by using Hebbian learning rules, and an operating phase wherein the trained oscillatory neuron network is used to recognize a pattern in an image, at least one of the training phase and the operating phase being computer-implemented.
G06V 10/82 - Dispositions pour la reconnaissance ou la compréhension d’images ou de vidéos utilisant la reconnaissance de formes ou l’apprentissage automatique utilisant les réseaux neuronaux
G06V 10/94 - Architectures logicielles ou matérielles spécialement adaptées à la compréhension d’images ou de vidéos
CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (CNRS) (France)
SORBONNE UNIVERSITE (France)
Inventeur(s)
Niguès, Antoine
Siria, Alessandro
Bocquet, Lydéric
Abrégé
The present invention relates to a device for measuring and/or modifying a surface of a sample, including a sample holder, including a first area configured to receive the sample fixedly mounted relative to the first area, a support, a first probe configured to detect a first parameter at a point of the surface and to generate a first measurement signal representative of the first parameter, and a second probe configured to detect a second parameter at a point of the surface, and to generate a second measurement signal representative of the second parameter, the first parameter being different from the second parameter, or one of the first probe and the second probe being configured to modify a third parameter of the surface at the point of the surface.
G01Q 60/04 - Microscopie à effet tunnel à balayage STM [Scanning Tunnelling Microscopy] combinée avec la microscopie à forces atomiques AFM [Atomic Force Microscopy]
G01Q 20/00 - Contrôle du mouvement ou de la position de la sonde
G01Q 30/14 - Moyens pour établir ou réguler des conditions ambiantes souhaitées au sein d'une enceinte d'échantillonnage avec fluide avec liquide
G01Q 40/00 - TECHNIQUES OU APPAREILS À SONDE À BALAYAGE; APPLICATIONS DES TECHNIQUES DE SONDE À BALAYAGE, p.ex. MICROSCOPIE À SONDE À BALAYAGE [SPM] Étalonnage, p.ex. des sondes
G01Q 60/16 - Sondes, leur fabrication ou leur instrumentation correspondante, p.ex. supports
G01Q 60/38 - Sondes, leur fabrication ou leur instrumentation correspondante, p.ex. supports
33.
HIGHLY DISPERSED METAL SUPPORTED OXIDE AS NH3-SCR CATALYST AND SYNTHESIS PROCESSES
CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (France)
UNIVERSITE CLAUDE BERNARD LYON 1 (France)
ECOLE SUPERIEURE DE CHIMIE PHYSIQUE ELECTRONIQUE DE LYON (France)
Inventeur(s)
Nguyen, Phuc Hai
Merle, Nicolas
Charlin, Marc-Olivier
Szeto, Kai Chung
Taoufik, Mostafa
Abrégé
A process for preparing a catalyst material, includes: (a) providing a support material having surface hydroxyl (OH) groups, the support material is ceria (CeO2), zirconia (ZrO2) or a combination, and the support material contains between 0.3 and 2.0 mmol OH groups/g of the support material; (b) reacting the support material with at least one of: (b1) a compound containing at least one alkoxy or phenoxy group bound though its oxygen atom to a metal element from Group 5 (V, Nb, Ta) or Group 6 (Cr, Mo, W); (b2) a compound containing at least one hydrocarbon group bound though a carbon atom to a metal element from Group 5 or 6; (b3) a compound containing at least one hydrocarbon group bound though a carbon atom to a metal element which is copper (Cu); and (c) calcining the product obtained in step (b).
B01J 31/02 - Catalyseurs contenant des hydrures, des complexes de coordination ou des composés organiques contenant des composés organiques ou des hydrures métalliques
B01J 31/16 - Catalyseurs contenant des hydrures, des complexes de coordination ou des composés organiques contenant des complexes de coordination
CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (France)
Inventeur(s)
Benabid, Fetah
Gerome, Frédéric
Amrani, Foued
Osorio, Jonas
Delahaye, Frédéric
Abrégé
An electromagnetic waveguide, such as an optical fibre, including a hollow central core surrounded by a microstructured sheath formed by an assembly of elementary cells, the microstructured sheath also including at least two elementary cells, at least one intermediate element connecting the elementary cells, the intermediate element having a cross-section with an area less than or equal to 50% of the cross-sectional area of each of the cells that it connects, the intermediate element having a refractive index less than or equal to the refractive index of each of the elementary cells that it connects.
ECOLE NATIONALE SUPERIEURE DE CHIMIE DE PARIS (USA)
CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (USA)
Inventeur(s)
Rousseau, Frédéric
Cramer, Jonathan
Prima, Frédéric
Morvan, Daniel
Abrégé
The invention relates to a process for treating, with a plasma, a composition comprising at least a first compound and a second compound, characterized in that said process comprises at least:
generating, within an enclosure, a non-equilibrium plasma flow from a gas present in said enclosure, and
treating the composition contained in said enclosure with said non-equilibrium plasma flow so as to extract at least a portion of said first compound.
CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (CNRS) (France)
ECOLE NORMALE SUPERIEURE DE LYON (France)
Inventeur(s)
Parola, Stéphane
Lopes, Cesar
Chateau, Denis
Chaput, Frederic
Abrégé
An optical structure comprising at least one stack having a central filter (1) and two sandwiching optical elements (2,3) between which the central filter (1) is interposed, wherein the central filter (1) is in a matrix material. The matrix material being doped with at least one doping agent, the central filter (1) and the two optical elements (2,3) on either side thereof being assembled by bonding layers (4a, 4b) of a material based on the same matrix material as that of the central filter, the optical elements (2,3) on either side of the central filter (1) and the bonding layers (4a, 4b) each having a refractive index equal to that of the material of the central filter or only differing from this refractive index within a range of plus or minus 0.05, preferably within a range of plus or minus 0.02.
ENZYMATIC DEGRADATION OF CRYSTALLIZABLE POLYMERS OR COPOLYMERS AND POST-CONSUMER/POST-INDUSTRIAL POLYMERIC MATERIALS CONTAINING CRYSTALLIZABLE POLYMERS OR COPOLYMERS
CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (France)
ECOLE SUPERIEURE DE PHYSIQUE ET DE CHIMIE INDUSTRIELLES DE LA VILLE DE PARIS (France)
SORBONNE UNIVERSITE (France)
Inventeur(s)
Garate, Hernan
Leibler, Ludwik
Freymond, Clément
Griffiths, Andrew
Breloy, Louise
Mansaku, Brian
Pallis, Jack
Abrégé
The present disclosure is related to systems and methods of enzymatic degradation of crystallizable polymers or copolymers and PC/IPM containing crystallizable polymers or copolymers.
C08J 11/10 - Récupération ou traitement des résidus des polymères par coupure des chaînes moléculaires des polymères ou rupture des liaisons de réticulation par voie chimique, p.ex. dévulcanisation
C08J 11/06 - Récupération ou traitement des résidus des polymères sans réaction chimique
C12N 9/18 - Hydrolases agissant sur les esters d'acides carboxyliques
C12N 9/20 - Scission des triglycérides, p.ex. au moyen de lipase
C12N 9/80 - Hydrolases (3.) agissant sur les liaisons carbone-azote autres que les liaisons peptidiques (3.5) agissant sur les liaisons amides des amides aliphatiques
B29B 17/00 - Récupération de matières plastiques ou d'autres constituants des déchets contenant des matières plastiques
B02C 19/00 - Autres dispositifs ou procédés de désagrégation
38.
OPTICAL SUBSTRATE HAVING INTEGRATED ANTENNAS, AND SPECTROMETER COMPRISING SAME
CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (France)
INSTITUT POLYTECHNIQUE DE GRENOBLE (France)
UNIVERSITE SAVOIE MONT BLANC (France)
Inventeur(s)
Martin, Guillerme
Morand, Alain
Abrégé
The invention relates to an optical substrate (1) having an integrated waveguide (2), at least one antenna (330) being formed in the optical substrate (1), the at least one antenna being formed by a plurality of nanoholes (341, 342, 343), at least one of the nanoholes (341, 342, 343) differing from the other nanoholes (341, 342, 343) by at least one of: its diameter, its spacing of the waveguide (2) in the height direction of the optical substrate (1), and its distance from an adjacent nanohole of the same antenna in the longitudinal direction of the optical substrate (1). The invention also relates to a spectrometer (S) that integrates an optical substrate (1) of this kind.
G02B 6/12 - OPTIQUE ÉLÉMENTS, SYSTÈMES OU APPAREILS OPTIQUES - Détails de structure de dispositions comprenant des guides de lumière et d'autres éléments optiques, p.ex. des moyens de couplage du type guide d'ondes optiques du genre à circuit intégré
B82Y 20/00 - Nano-optique, p.ex. optique quantique ou cristaux photoniques
G02B 6/124 - Lentilles géodésiques ou réseaux intégrés
G02B 6/293 - Moyens de couplage optique ayant des bus de données, c. à d. plusieurs guides d'ondes interconnectés et assurant un système bidirectionnel par nature en mélangeant et divisant les signaux avec des moyens de sélection de la longueur d'onde
39.
METHOD FOR DETERMINING THE LITHIUM CONTENT IN A BIOLOGICAL FLUID
CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (France)
UNIVERSITÉ DE FRANCHE-COMTÉ (France)
CENTRE HOSPITALIER RÉGIONAL UNIVERSITAIRE DE BESANCON (France)
Inventeur(s)
Wacogne, Bruno
Azzopardi, Charles-Louis
Gauthier-Manuel, Bernard
Charriere, Karine
Abrégé
Method for determining an amount of lithium contained in a biological fluid, said method comprising the steps consisting in adding, to a biological fluid sample of known volume, a given volume of a discriminating solution, the effect of which is to obtain a biological fluid solution buffered at a pH of between 6 and 8 and to bring about precipitation of at least a portion of the cations contained in the biological fluid sample except for the lithium Ions. The method further comprises the steps consisting in depositing a given volume of biological fluid solution onto an active layer (2) of an optode (1), said active layer comprising a chemical transducer of which at least one optical property is modified In the presence of lithium ions in the biological fluid solution, in measuring at least one characteristic of at least one light wave emitted or reflected by the active layer of the optode and in determining, from the at least one measured characteristic and from calibration data, an amount of lithium contained in the biological fluid.
G01N 21/78 - Systèmes dans lesquels le matériau est soumis à une réaction chimique, le progrès ou le résultat de la réaction étant analysé en observant l'effet sur un réactif chimique produisant un changement de couleur
G01N 21/82 - Systèmes dans lesquels le matériau est soumis à une réaction chimique, le progrès ou le résultat de la réaction étant analysé en observant l'effet sur un réactif chimique produisant un précipité ou une turbidité
40.
COMBINATION OF A BTN3A ACTIVATING ANTIBODY, A BCL2 INHIBITOR AND HYPOMETHYLATING AGENT FOR USE IN TREATING CANCER
INSTITUT NATIONAL DE LA SANTÉ ET DE LA RECHERCHE MÉDICALE (France)
CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (France)
UNIVERSITÉ D'AIX-MARSEILLE (France)
INSTITUT JEAN PAOLI & IRENE CALMETTES (France)
Inventeur(s)
Le Floch, Anne-Charlotte
Olive, Daniel
Vey, Norbert
Frohna, Paul
Wieduwild, Elisabeth
Makadamutil, Loui
Abrégé
The present invention relates a therapeutic combination of a BTN3A activating antibody, a Bcl-2 family inhibitor and hypomethylating agents that is particularly useful for the treatment of cancer, in particular hematological malignancies. The present disclosure more particularly relates to the combined use of a BTN3A activating antibody that activates the cytolytic function of Vγ9Vδ2 T cells, and of Venetoclax, which selectively inhibits the Bcl2 receptor, and hypomethylating agents such as Azacytidine, to promote synergistically and specifically Vγ9Vδ2 T cell anticancer activity.
C07K 16/30 - Immunoglobulines, p.ex. anticorps monoclonaux ou polyclonaux contre du matériel provenant d'animaux ou d'humains contre des récepteurs, des antigènes de surface cellulaire ou des déterminants de surface cellulaire provenant de cellules de tumeurs
A61P 35/02 - Agents anticancéreux spécifiques pour le traitement de la leucémie
C07K 16/28 - Immunoglobulines, p.ex. anticorps monoclonaux ou polyclonaux contre du matériel provenant d'animaux ou d'humains contre des récepteurs, des antigènes de surface cellulaire ou des déterminants de surface cellulaire
A61K 31/635 - Composés contenant des groupes para-N-benzènesulfonyl-N-, p.ex. sulfanilamide, p-nitrobenzènesulfonohydrazide contenant un hétérocycle, p.ex. sulfadiazine
A61K 31/706 - Composés ayant des radicaux saccharide et des hétérocycles ayant l'azote comme hétéro-atome d'un cycle, p.ex. nucléosides, nucléotides contenant des cycles à six chaînons avec l'azote comme hétéro-atome d'un cycle
A61K 45/06 - Mélanges d'ingrédients actifs sans caractérisation chimique, p.ex. composés antiphlogistiques et pour le cœur
INSTITUT NATIONAL DE LA SANTÉ ET DE LA RECHERCHE MÉDICALE (France)
CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (France)
CENTRE HOSPITALIER UNIVERSITAIRE DE TOULOUSE (France)
UNIVERSITÉ TOULOUSE III – PAUL SABATIER (France)
Inventeur(s)
Galinier, Anne
Dray, Cédric
Labaste, François
Stephan, Marion
Pey, Vincent
Minville, Vincent
Abrégé
Circulatory failure generates hypoxia and leads to accumulation of reductive species in tissue and circulatory failure monitoring tools are needed but rare. Cardiopulmonary bypass (CPB) is known to promote brief circulatory failure during its initiation. In the present study, the Inventors demonstrate a correlation between whole blood redox potential and circulatory failure during (CPB). They made a prospective study with 17 patients eligible for cardiac surgery with cardiopulmonary bypass. They demonstrated a frank reduction of the whole blood redox potential during circulatory failure during the initiation of CPB. They also demonstrated that they were able to classify patients in 3 groups, one of them presenting an unfavorable post-operative outcome. Accordingly, the present invention relates to a method of diagnosing acute circulatory failure in a patient comprising determining the level of redox potential in a sample obtained from said patient, wherein the level of redox potential indicates whether the patient suffers or not from an acute circulatory failure.
ECOLE NATIONALE SUPERIEURE DE CHIMIE DE MONTPELLIER (ENSCM) (France)
UNIVERSITE DE MONTPELLIER (UM) (France)
CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (France)
Inventeur(s)
Laconde, Guillaume
Martinez, Jean
Amblard-Caussil, Muriel
Abrégé
A novel method for synthesizing NCA compounds. Also, a new use of a peptide coupling agent. The method makes it possible to obtain NCA compounds from α-amino-acids, under mild and non-racemic reaction conditions, and in the absence of constraining reagents of use, such as phosgene, which may lead to the formation of undesirable by-products.
C07D 413/06 - Composés hétérocycliques contenant plusieurs hétérocycles, au moins un cycle comportant des atomes d'azote et d'oxygène comme uniques hétéro-atomes du cycle contenant deux hétérocycles liés par une chaîne carbonée contenant uniquement des atomes de carbone aliphatiques
C07D 263/06 - Composés hétérocycliques contenant des cycles oxazole-1, 3 ou oxazole-1, 3 hydrogéné non condensés avec d'autres cycles ne comportant pas de liaisons doubles entre chaînons cycliques ou entre chaînons cycliques et chaînons non cycliques avec des radicaux hydrocarbonés, substitués par des atomes d'oxygène, liés aux atomes de carbone du cycle
Institut National De La Sante Et De La Recherche Medicale (INSERM) (France)
Centre National De La Recherche Scientifique (CNRS) (France)
Ecole Normale Superieure De Lyon (France)
Universite Claude Bernard Lyon 1 (France)
Inventeur(s)
Ohlmann, Théophile
Mangeot, Philippe
Ricci, Emiliano
Abrégé
The present invention relates to a virus-derived particle comprising one or more Cas protein(s), as well as to kits and methods using the same for altering a target nucleic acid.
CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (France)
UNIVERSITE DE BORDEAUX (France)
INSTITUT POLYTECHNIQUE DE BORDEAUX (France)
UNIVERSITE GRENOBLE ALPES (France)
Inventeur(s)
Chevalier, Xavier
Sérégé, Matthieu
Gomes Correia, Cindy
Zelsmann, Marc
Fleury, Guillaume
Abrégé
The invention relates to a method of directional self-assembly lithography, said method comprising a step of depositing a block copolymer film on a layer (20) neutral with respect the block copolymer, said block copolymer film being for use as a lithography mask, said method being characterized in that it comprises the following steps of:
depositing said neutral layer (20) on a surface of a substrate (10), said neutral layer (20) being of the carbon or fluoro-carbon type deposited to a thickness greater than 1.5 times the thickness of the block copolymer film (40),
crosslinking said neutral layer,
depositing said block copolymer film, comprising at least one silylated block, on said crosslinked neutral layer (30),
subjecting the stack to an assembly temperature in order to nanostructure said block copolymer,
removing (G1) at least one of the nano-domains (41, 42) from the nanostructured block copolymer film (40), in order to create a pattern intended to be transferred by etching (G2, G3, G4) into the thickness of the substrate (10).
G03F 7/00 - Production par voie photomécanique, p.ex. photolithographique, de surfaces texturées, p.ex. surfaces imprimées; Matériaux à cet effet, p.ex. comportant des photoréserves; Appareillages spécialement adaptés à cet effet
45.
DEPOSITION OF MATERIAL LAYERS BY EVAPORATION AND DUAL ACTIVATION
CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (France)
UNIVERSITE PARIS-SACLAY (France)
Inventeur(s)
Richardt, Isabelle
Moreau, Jérémy
Hamouda, Frédéric
Aassime, Abdelhanin
Abrégé
Deposition of a material such as indium in the form of nitrided thin layers, by evaporation and dual activation using a nitrogen plasma (41) and an electron beam (42).
C23C 14/00 - Revêtement par évaporation sous vide, pulvérisation cathodique ou implantation d'ions du matériau composant le revêtement
C23C 14/06 - Revêtement par évaporation sous vide, pulvérisation cathodique ou implantation d'ions du matériau composant le revêtement caractérisé par le matériau de revêtement
C23C 14/26 - Evaporation sous vide par chauffage de la source par induction ou par résistance
CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (France)
INSTITUT NATIONAL DES SCIENCES APPLIQUEES DE LYON (France)
ECOLE SUP CHIMIE PHYS ELECTRONIQ LYON (France)
Inventeur(s)
Marquette, Christophe
Zaidi, Hamza Raza
Abrégé
The invention relates in particular to a cell culture device comprising an insert (1) having an internal cavity (11) delimited by an insert side wall (12) and an insert bottom (10), said internal cavity being able to receive said cell culture in a cell culture fluid so as to create a cell tissue (2). The device comprises a container (3) that removably receives said insert, said side wall (12) having first through-holes (13). The container comprises an internal flue (30) and an opening (33) which allows said insert (1) to be inserted into said flue. The insert bottom comprises second through-holes (14) allowing observation of the cells therethrough, said first and second through-holes being capillary holes able to retain said cell culture fluid in said internal cavity and serving to anchor said cell tissue.
CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (France)
THE TRUSTEES OF PRINCETON UNIVERSITY (USA)
Inventeur(s)
Pupillo, Guido
Jandura, Sven
Thompson, Jeffrey
Abrégé
A method for optimizing a quantum operation to be applied on two quantum objects of a system of quantum objects The present invention relates to a method for optimizing a quantum operation to be applied on at least two quantum objects (12) of a system (10) of quantum objects, the method comprising the determination of an optimized pulse to be generated by at least one controlled laser for implementing the quantum operation on the at least two quantum objects (12) while fulfilling a robustness criterion, the at least two quantum objects (12) having a quantum state depending on the excitation level of the at least two quantum objects, the excitation level being chosen between 01, 10 and 11, 0 defining a de-excited state for a quantum object and 1 defining an excited state for a quantum object, the quantum state having a zero order term and a first order term.
G06N 10/40 - Réalisations ou architectures physiques de processeurs ou de composants quantiques pour la manipulation de qubits, p.ex. couplage ou commande de qubit
48.
OPTICAL DEVICE FOR SELF-REFERENCED FULL-FIELD TEMPORAL OPTICAL COHERENCE TOMOGRAPHY MICROSCOPIC IMAGING, AND ASSOCIATED FACILITY AND METHOD
CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (France)
INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE (France)
ECOLE SUPERIEURE DE PHYSIQUE ET DE CHIMIE INDUSTRIELLES DE LA VILLE DE PARIS (France)
CENTRE HOSPITALIER D'OPHTALMOLOGIE DES QUINZE-VINGTS (France)
Inventeur(s)
Grieve, Kate
Thouvenin, Olivier
Monfort, Tual
Azzollini, Salvatore
Reichman, Sacha
Abrégé
The invention relates to an optical device for the full-field optical coherence tomography microscopic imaging of at least one sample, the device comprising a lens for observing the sample when in use, the device comprising a specular interface, the device thus being able, when in use, to allow the production of at least one interference between at least one reference wave obtained by the reflection of light emitted by a light source associated with the device from the specular interface, and at least one object wave obtained by the backscattering of the light emitted by the source from the sample, the specular interface being arranged with respect to the lens in such a way that, when in use, the object wave passes through the specular interface on its path between the sample and the source. The invention also relates to the corresponding facility and method.
CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (France)
CENTRALESUPELEC (France)
SAFRAN ELECTRONICS & DEFENSE (France)
Inventeur(s)
Pouilly-Cathelain, Maxime
Feyel, Philippe
Attrazic, Yannick Ghislain Sébastien Xavier
Duc, Gilles
Sandou, Guillaume
Abrégé
One aspect of the invention relates to a method (100) for controlling a mechatronic system, based on a model for predicting the behaviour of the mechatronic system and a cost function ensuring compliance with constraints by the mechatronic system, with a view to following path instructions to a prediction horizon, the method comprising: reformulating (10) the constraints into barrier functions and integrating the barrier functions into the cost function; and for each sampling period of a sequence of sampling periods: obtaining (20) the path instructions and at least one measurement of the mechatronic system in a current state; determining (30) coefficients of a polynomial of order m using a Nelder-Mead method optimizing the cost function based on the predicting model, this determining step receiving as input the path instructions and the at least one measurement of the mechatronic system obtained (20); computing (40) a command through evaluation of the polynomial; and applying (50) the command to the mechatronic system.
G05B 13/02 - Systèmes de commande adaptatifs, c. à d. systèmes se réglant eux-mêmes automatiquement pour obtenir un rendement optimal suivant un critère prédéterminé électriques
G05B 13/04 - Systèmes de commande adaptatifs, c. à d. systèmes se réglant eux-mêmes automatiquement pour obtenir un rendement optimal suivant un critère prédéterminé électriques impliquant l'usage de modèles ou de simulateurs
50.
THERAPY BY TRANS-SPLICING OF OPA1 PRE-MESSENGER RNAS FOR THE TREATMENT OF DISEASES ASSOCIATED WITH OPA1 GENE MUTATIONS
C12N 15/85 - Vecteurs ou systèmes d'expression spécialement adaptés aux hôtes eucaryotes pour cellules animales
A61K 48/00 - Préparations médicinales contenant du matériel génétique qui est introduit dans des cellules du corps vivant pour traiter des maladies génétiques; Thérapie génique
C12N 5/10 - Cellules modifiées par l'introduction de matériel génétique étranger, p.ex. cellules transformées par des virus
INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE (France)
UNIVERSITE TOULOUSE III-PAUL SABATIER (France)
CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (France)
CENTRE HOSPITALIER UNIVERSITAIRE DE TOULOUSE (France)
Inventeur(s)
Espagnolle, Nicolas, Lucien
Gadelorge, Mélanie, Alexandra
Corre, Jill
Abrégé
The present invention relates to the method for producing a three-dimensional (3D) model of multiple myeloma (MM), in the form of spheroids, by co-culturing stem cells/mesenchymal stromal cells, endothelial progenitors and primary plasma cells of one or more MM patients. The present invention also relates to the spheroids obtained by said method, and uses thereof.
CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (France)
INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE (France)
ASSISTANCE PUBLIQUE HOPITAUX DE PARIS (France)
UNIVERSITE PARIS CITE (France)
Inventeur(s)
Couture, Olivier
Hingot, Vincent
Denis, Louise
Aissani, Abderrahmane
Bodard, Sylvain
Correas, Jean-Michel
Abrégé
The present invention relates to a method for ultrasound imaging of a microvascular structure, which method characterised in that it comprises: - a step of injecting ultrasound contrast agents into blood vessels in a region comprising a microvascular structure, - a step of ultrasound imaging the region comprising the microvascular structure while the contrast agents flow through the blood vessels, the concentration of the contrast agents and/or the ultrasound frequency of the imaging being chosen such that the contrast agents are sufficiently separated to prevent feedback, - a step of detecting/filtering and locating the contrast agents, - a step of individually monitoring the contrast agents, - a step of classifying the behaviours of the individually monitored contrast agents according to at least one predetermined behaviour characteristic of contrast agents flowing through the microvascular structure, and - a step of imaging the microvascular structure according to the thus-performed classification.
CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (CNRS) (France)
INSERM (Institut National de la Sante et de la Recherche Medicale) (France)
UNIVERSITE CLAUDE BERNARD LYON 1 (France)
Inventeur(s)
Diaz, Jean-Jacques
Marcel-Terrier, Virginie
Kielbassa, Janice
Catez, Frédéric
Abrégé
The present invention relates to a method for identifying potentially relevant markers in cancer diagnosis, prognosis and/or therapy, comprising an analysis approach which is based on the detection of variations in methylation of ribosomal RNAs in a biological sample. The present invention also relates to several applications of this analysis approach for determining the cancer subtype and/or the prognosis of a patient suffering from cancer, for estimating or assessing the benefit of a treatment in such patient, but also for selecting one or more therapeutic drug(s) targeting ribosomes useful for treating cancers.
C12Q 1/6886 - Produits d’acides nucléiques utilisés dans l’analyse d’acides nucléiques, p.ex. amorces ou sondes pour les maladies provoquées par des altérations du matériel génétique pour le cancer
CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (France)
Inventeur(s)
Maenner, Sylvain
Behm-Ansmant, Isabelle
Alfeghaly, Charbel
Abrégé
The present invention relates to an isolated double stranded DNA polynucleotide that forms triplex with sequence 5′-GGUGGCAGCAAGAGAAAAAUGAGGAAGAAGCAAAAGCGGAAA-3′ (SEQ ID NO: 1) of the long non-coding RNA ANRIL (Antisense Non-coding RNA in the INK4 Locus). It also relates to a vector comprising the double stranded DNA polynucleotide, and to a pharmaceutical composition comprising the double stranded DNA polynucleotide or the vector. The present invention relates as well to the isolated double stranded DNA polynucleotide for use in the treatment of myocardial infarction, aneurysms, stenosis, myocardial infarction, aneurysms, cancers, eye diseases or type 2 diabetes.
C12N 15/63 - Introduction de matériel génétique étranger utilisant des vecteurs; Vecteurs; Utilisation d'hôtes pour ceux-ci; Régulation de l'expression
55.
CHARACTERIZATION OF A RADIATION PULSE BY TIME-RESOLVED OPTICAL GATING
CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE - CNRS - (France)
Inventeur(s)
Bejot, Pierre
Billard, Franck
Hertz, Edouard
Abrégé
A system for characterizing a pulse of electromagnetic radiation by time-resolved optical gating, which includes an interference-forming device which is adapted for superimposing four parts of the pulse. The system also includes a matrix image sensor which selectively captures, based on two-photon absorptions, an interference pattern formed by the pulse. The system allows obtaining the pulse shape completely and accurately, and is particularly suitable for characterizing ultrashort pulses. Also, the two-photon absorption can be produced in the matrix image sensor, or replaced by optical frequency doubling which is produced by an SHG crystal plate.
H04N 23/12 - Caméras ou modules de caméras comprenant des capteurs d'images électroniques; Leur commande pour générer des signaux d'image à partir de différentes longueurs d'onde avec un seul capteur
56.
BIOFUNCTIONAL ELECTRODE FOR STORING AND RELEASING COMPOUNDS BY SLOW DIFFUSION
CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (France)
UNIVERSITE DE LORRAINE (France)
UNIVERSITE GRENOBLE ALPES (France)
Inventeur(s)
Cosnier, Serge
Mc Murtry, Stefan
El Mazria, Omar
Riahi, Hanna
Nedellec, Yannig
Abrégé
An electrode including a storage film. The storage film includes a layer of a support material including at least one inclusion in which a compound of interest is stored and a wall of permeable sealing material sealing the at least one inclusion. The storage film further includes a porous layer covering, at least in part, the wall of sealing material, at least a portion of a surface of the porous layer constituting an active surface of the electrode.
H01M 8/16 - PROCÉDÉS OU MOYENS POUR LA CONVERSION DIRECTE DE L'ÉNERGIE CHIMIQUE EN ÉNERGIE ÉLECTRIQUE, p.ex. BATTERIES Éléments à combustible; Leur fabrication Éléments à combustible biochimique, c. à d. éléments dans lesquels des micro-organismes agissent comme catalyseurs
57.
SYNERGISTIC EFFECT OF A FXR AGONIST AND IFN FOR THE TREATMENT OF HBV INFECTION
A61K 31/46 - Aza-8-bicyclo[3.2.1]octane; Ses dérivés, p.ex. atropine, cocaïne
A61K 31/575 - Composés contenant des systèmes cycliques du cyclopenta[a]hydrophénanthrène; Leurs dérivés, p.ex. stéroïdes substitués en position 17 bêta par une chaîne d'au moins trois atomes de carbone, p.ex. cholane, cholestane, ergostérol, sitostérol
A61K 45/06 - Mélanges d'ingrédients actifs sans caractérisation chimique, p.ex. composés antiphlogistiques et pour le cœur
A61K 47/60 - Préparations médicinales caractérisées par les ingrédients non actifs utilisés, p.ex. les supports ou les additifs inertes; Agents de ciblage ou de modification chimiquement liés à l’ingrédient actif l’ingrédient non actif étant chimiquement lié à l’ingrédient actif, p.ex. conjugués polymère-médicament l’ingrédient non actif étant un agent de modification l’agent de modification étant un composé organique macromoléculaire, p.ex. une molécule oligomérique, polymérique ou dendrimérique obtenu par des réactions autres que celles faisant intervenir uniquement des liaisons non saturées carbone-carbone, p.ex. polyurées ou polyuréthanes le composé organique macromoléculaire étant un oligomère, un polymère ou un dendrimère de polyoxyalkylène, p.ex. PEG, PPG, PEO ou polyglycérol
A61P 31/20 - Antiviraux pour le traitement des virus ADN
58.
RADICALLY POLYMERIZABLE COMPOSITION COMPRISING A REDOX INITIATOR SYSTEM BASED ON DIHYDROPYRIDINES
Centre National de la Recherche Scientifique (France)
Universite de Haute Alsace (France)
Inventeur(s)
Fässler, Pascal
Lamparth, Iris
Catel, Yohann
Schnur, Thomas
Lalevée, Jacques
Thetiot, Estelle
Abrégé
Radically polymerizable dental material, which includes a catalyst paste and a base paste, wherein the catalyst pastes includes an oxidizing agent, preferably a peroxide or hydroperoxide, a radically polymerizable monomer and/or oligomer with acid group and a polyfunctional radically polymerizable monomer, and the base paste comprises a polyfunctional radically polymerizable monomer without an acid group and a dihydropyridine derivative of Formula (1)
Radically polymerizable dental material, which includes a catalyst paste and a base paste, wherein the catalyst pastes includes an oxidizing agent, preferably a peroxide or hydroperoxide, a radically polymerizable monomer and/or oligomer with acid group and a polyfunctional radically polymerizable monomer, and the base paste comprises a polyfunctional radically polymerizable monomer without an acid group and a dihydropyridine derivative of Formula (1)
Radically polymerizable dental material, which includes a catalyst paste and a base paste, wherein the catalyst pastes includes an oxidizing agent, preferably a peroxide or hydroperoxide, a radically polymerizable monomer and/or oligomer with acid group and a polyfunctional radically polymerizable monomer, and the base paste comprises a polyfunctional radically polymerizable monomer without an acid group and a dihydropyridine derivative of Formula (1)
The material has good mechanical properties and does not exhibit a bitter taste.
CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (France)
INSTITUT MINES TÉLÉCOM (France)
Inventeur(s)
Thers, Dominique
Stutzmann, Jean-Sébastien
Abrégé
A method for monitoring a hadron beam during hadron-therapy treatment of a subject including tumour cells labelled with a radiopharmaceutical product, in which the hadron beam includes a plurality of discrete hadron bursts, the method including the following steps: when a burst impacts on the subject, detecting the prompt gamma generated by the interaction of the hadrons of the burst with the tissues of the subject using a Compton telescope and reconstructing an image of the interaction volume; when no burst impacts on the subject, extracting the position of the tumour cells labelled with the radiopharmaceutical product using the Compton telescope and reconstructing an image of the total volume of the tumour; comparing the image of the interaction volume and the image of the total volume of the tumour so as to locate the measured interaction volume relative to the measured total volume of the tumour.
INSTITUT NATIONAL DE LA SANTÉ ET DE LA RECHERCHE MÉDICALE (France)
ASSISTANCE PUBLIQUE HÔPITAUX DE PARIS (France)
SORBONNE UNIVERSITÉ (France)
UNIVERSITÉ PARIS CITÉ (France)
CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (France)
Inventeur(s)
Poulet, Geoffroy
Galichon, Pierre
Anglicheau, Dany
Taly, Valérie
Péré, Hélène
Veyer, David
Laurent-Puig, Pierre
Beinse, Guillaume
Abrégé
The present invention relates to a kit and an in vitro method for detecting and characterizing the degradation of a particular organ or tissue, on the basis of the analysis of the presence of at least one specific methylated cell-free DNA in a biological sample. More particularly, the invention relates to a kit and a method for detecting and characterizing the degradation of an organ selected from: the brain, the lung and the kidney, and/or of a tissue present in this organ. The invention also relates to a method for the in vitro diagnosis of a disease or condition involving the lysis of an organ or tissue.
C12Q 1/6883 - Produits d’acides nucléiques utilisés dans l’analyse d’acides nucléiques, p.ex. amorces ou sondes pour les maladies provoquées par des altérations du matériel génétique
G01N 21/77 - Systèmes dans lesquels le matériau est soumis à une réaction chimique, le progrès ou le résultat de la réaction étant analysé en observant l'effet sur un réactif chimique
C01G 15/00 - Composés du gallium, de l'indium ou du thallium
G01N 33/84 - Analyse chimique de matériau biologique, p.ex. de sang ou d'urine; Test par des méthodes faisant intervenir la formation de liaisons biospécifiques par ligands; Test immunologique faisant intervenir des composés inorganiques ou le pH
G01N 21/70 - Systèmes dans lesquels le matériau analysé est excité de façon à ce qu'il émette de la lumière ou qu'il produise un changement de la longueur d'onde de la lumière incidente excité mécaniquement, p.ex. par triboluminescence
G01N 33/58 - Analyse chimique de matériau biologique, p.ex. de sang ou d'urine; Test par des méthodes faisant intervenir la formation de liaisons biospécifiques par ligands; Test immunologique faisant intervenir des substances marquées
62.
METHOD AND DEVICE FOR ASSISTING THE DETERMINATION OF AN ANTIOXIDANT DOSAGE FOR A PERSON SUFFERING FROM OXIDATIVE STRESS
CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (France)
INSTITUT NATIONAL DE LA SANTÉ ET DE LA RECHERCHE MÉDICALE (France)
CENTRE HOSPITALIER UNIVERSITAIRE DE MONTPELLIER (France)
Inventeur(s)
Laoudj-Chenivesse, Dalila
Abrégé
The invention relates to a method (100) for assisting the determination of a dosage of antioxidants to be administered to a patient suffering from oxidative stress, said method (100) comprising at least one iteration of a prediction phase (108) comprising the following steps: - measurement (110), on a blood sample previously taken from said patient, of a level of at least the following input parameters: cholesterol level, zinc level, copper level, vitamin C level, vitamin E level, and selenium level; - estimation (130) of a dosage for at least one antioxidant to be administered to said patient, via a previously trained estimation model, executed by a calculation unit, said estimation model taking as input said at least one input parameter. The invention also relates to a device which implements such a method.
G16H 20/10 - TIC spécialement adaptées aux thérapies ou aux plans d’amélioration de la santé, p.ex. pour manier les prescriptions, orienter la thérapie ou surveiller l’observance par les patients concernant des médicaments ou des médications, p.ex. pour s’assurer de l’administration correcte aux patients
63.
- DEVICE AND METHOD FOR CHARACTERIZING CELLS SUBJECTED TO A PHYSICAL STRESS
CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (France)
UNIVERSITÉ CLAUDE BERNARD LYON 1 (France)
INSTITUT NATIONAL DES SCIENCES APPLIQUEES DE LYON (France)
ECOLE SUP CHIMIE PHYS ELECTRONIQ LYON (France)
Inventeur(s)
Courtial, Edwin-Joffrey
Petiot, Emma
Maleki, Mehdi
Halima, Imen
Frossard, Gabriel
Abrégé
The present invention relates to a microfluidic device and to a method for applying at least one hydrodynamic stress of defined intensity and duration to cells in suspension, said cell being in motion in said device, and for characterizing the morphology and the physiological state of these cells during, and optionally after, the application of the hydrodynamic stress.
G01N 15/14 - Recherche par des moyens électro-optiques
C12M 1/42 - Appareils pour le traitement de micro-organismes ou d'enzymes au moyen d'énergie électrique ou ondulatoire, p.ex. magnétisme, ondes sonores
B01L 3/00 - Récipients ou ustensiles pour laboratoires, p.ex. verrerie de laboratoire; Compte-gouttes
64.
METHOD FOR PRODUCING ONE OR SEVERAL SHARED CANCER EPITOPE(S) DERIVED FROM ALTERNATIVE TRANSLATIONAL CONTROL
INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE (INSERM) (France)
CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (France)
Inventeur(s)
Depil, Stéphane
Baulu, Estelle
Chuvin, Nicolas
Diaz, Jean-Jacques
Marcel, Virginie
Dalla Venezia, Nicole
Abrégé
The present invention relates to a method for producing or identifying one or several shared cancer epitope(s), as well as peptides comprising or consisting of the epitopes identified or produced by said method, expression vectors encoding said peptides, cytotoxic T lymphocytes (CTLs) generated in vitro by stimulation of T cells with the said peptides or vectors, CTLs of a subject treated with said peptides or vectors, and engineered T cells expressing T-cell receptors recognizing said peptides. The present invention also relates to the use of said peptides, expression vectors, CTLs or engineered T cells as a vaccine or a medicament, and in particular, the use of said peptides, expression vectors, CTLs, or engineered T cells for preventing or treating at least one cancer in a subject in need thereof.
INSTITUT NATIONAL DE LA SANTÉ ET DE LA RECHERCHE MÉDICALE (France)
CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (France)
UNIVERSITE PARIS CITE (France)
UNIVERSITE PARIS-SACLAY (France)
Inventeur(s)
Michel, Laurence
Sintès, Maxime
Albert, Claire
Agnely, Florence
Beladjine, Mohamed Amine
Huang, Nicolas
Tsapis, Nicolas
Haine Hablal, Liasmine
Abrégé
Oil-in-water Pickering emulsion comprising: an oil phase comprising a first therapeutic agent, an aqueous phase, polyester nanoparticles comprising a second therapeutic agent, wherein the oil phase is in the form of droplets and is dispersed in a continuous aqueous phase, and wherein at least a portion of the nanoparticles are localized at an interface between the oil phase and the aqueous phase, characterized in that the aqueous phase comprises hyaluronan. This new emulsion allows the topical treatment of inflammatory dermatoses such as psoriasis, atopic dermatitis or prurigo, benign skin inflammations such as inflammatory acne, scalp pathologies such asalopecia, dermo-cosmetic conditions, such as very dry irritable skin, tumor pathologies such as mycosis fungoides (indolent cutaneous T lymphoma) or cutaneous mastocytosis (accumulation and abnormal proliferation of mast cells in the dermis, with intense pruritus), and fibrosing pathologies such as keloids (raised, pruritic dystrophic scars, which have the particularity of not regressing spontaneously and of being able to extend beyond the traumatic/injured area).
A61K 31/436 - Composés hétérocycliques ayant l'azote comme hétéro-atome d'un cycle, p.ex. guanéthidine ou rifamycines ayant des cycles à six chaînons avec un azote comme seul hétéro-atome d'un cycle condensés en ortho ou en péri avec des systèmes hétérocycliques le système hétérocyclique contenant un cycle à six chaînons ayant l'oxygène comme hétéro-atome du cycle, p.ex. rapamycine
A61K 31/515 - Acides barbituriques; Leurs dérivés, p.ex. pentobarbital sodique
A61K 31/593 - Dérivés du 9,10-séco-cholestane, p.ex. cholécalciférol, vitamine D3
CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (France)
INSERM (INSTITUT NATIONAL DE LA SANTÉ ET DE LA RECHERCHE MÉDICALE) (France)
Inventeur(s)
Francois, Quentin
Duplat, Bertrand
Haliyo, Sinan
Régnier, Stéphane
Zarader, Pierre
Couture, Olivier
Coudert, Antoine
Abrégé
A system to localize a micro-device inside a target body part, including: a micro-device remotely steered and controlled from outside the target body part, a control unit including a memory for storing one ultrasound image of the target body part, one probe being brought in contact with a securing body part of the patient, and at least one tracker connected to the micro-device. The probe and the tracker communicate with ultrasounds, the control unit being thus able to localize, in real time, the tracker within an internal referential defined with regards to the probe, and the control unit displays, on a screen, the ultrasound image and displays, in real time, the localization of the micro-device on the ultrasound image.
A61B 90/00 - Instruments, outillage ou accessoires spécialement adaptés à la chirurgie ou au diagnostic non couverts par l'un des groupes , p.ex. pour le traitement de la luxation ou pour la protection de bords de blessures
A61B 8/00 - Diagnostic utilisant des ondes ultrasonores, sonores ou infrasonores
A61B 8/08 - Détection de mouvements ou de changements organiques, p.ex. tumeurs, kystes, gonflements
A61B 34/20 - Systèmes de navigation chirurgicale; Dispositifs pour le suivi ou le guidage d'instruments chirurgicaux, p.ex. pour la stéréotaxie sans cadre
A61B 17/00 - Instruments, dispositifs ou procédés chirurgicaux, p.ex. tourniquets
68.
USE OF THE EMM ANTIGEN AS A BIOMARKER OF INHERITED GPI DEFICIENCIES
INSTITUT NATIONAL DE LA SANTÉ ET DE LA RECHERCHE MÉDICALE (France)
ASSISTANCE PUBLIQUE - HÔPITAUX DE PARIS (France)
CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (CNRS) (France)
FONDATION IMAGINE (France)
UNIVERSITÉ PARIS CITÉ (France)
UNIVERSITE ANTILLES GUYANE (France)
ETABLISSEMENT FRAN¿AIS DU SANG (EFS) (France)
Inventeur(s)
Peyrard, Thierry
Azouzi, Slim
Hermine, Oliver
Colin-Aronovicz, Yves
Duval, Romain
Le Van Kim, Caroline
Abrégé
Glycosylphosphatidylinositol (GPI) is a glycolipid that anchors more than 150 proteins to the cell surface. Pathogenic variants in several genes that participate in GPI biosynthesis cause inherited GPI deficiency (IGD) disorders. Here, the inventors reported that homozygous null alleles of PIGG, a gene involved in GPI modification, are responsible for the rare Emm-negative blood phenotype. Using a panel of K562 cells defective in both the GPI-transamidase and GPI remodeling pathways, they demonstrate that the Emm antigen, whose molecular basis has remained unknown for decades, is carried only by free GPI and that its epitope is composed of the second and third ethanolamine of the GPI backbone. Importantly, the inventors show that the decrease in Emm expression in several IGD patients is indicative of GPI defects. Overall, our findings establish Emm as a novel blood group system and have important implications for understanding the biological function of human free GPI.
G01N 33/68 - Analyse chimique de matériau biologique, p.ex. de sang ou d'urine; Test par des méthodes faisant intervenir la formation de liaisons biospécifiques par ligands; Test immunologique faisant intervenir des protéines, peptides ou amino-acides
G01N 33/80 - Analyse chimique de matériau biologique, p.ex. de sang ou d'urine; Test par des méthodes faisant intervenir la formation de liaisons biospécifiques par ligands; Test immunologique faisant intervenir les groupes ou les types sanguins
69.
COMPOSITIONS AND METHODS FOR CANCER IMAGING AND RADIOTHERAPY
CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (France)
UNIVERSITE D'AIX-MARSEILLE (France)
Inventeur(s)
Malicet, Cédric
Lecorche, Pascaline
Nowak, Jonathan
David, Marion
Temsamani, Jamal
Khrestchatisky, Michel
Abrégé
The present invention relates to a conjugated compound comprising a marker M pharmaceutically acceptable, and a peptide or pseudo-peptide P having at most 30 amino acid residues and able to bind the Low-Density Lipoprotein Receptor (LDLR) and to its use in a method of labelling and/or detecting and/or treating cancerous cells in a subject by administration of the conjugated compound to the subject an analysis of the presence and/or the amount of marker.
C07K 7/06 - Peptides linéaires ne contenant que des liaisons peptidiques normales ayant de 5 à 11 amino-acides
G01N 33/574 - Tests immunologiques; Tests faisant intervenir la formation de liaisons biospécifiques; Matériaux à cet effet pour le cancer
G01N 33/60 - Analyse chimique de matériau biologique, p.ex. de sang ou d'urine; Test par des méthodes faisant intervenir la formation de liaisons biospécifiques par ligands; Test immunologique faisant intervenir des substances marquées faisant intervenir des substances marquées radioactives
G01N 33/92 - Analyse chimique de matériau biologique, p.ex. de sang ou d'urine; Test par des méthodes faisant intervenir la formation de liaisons biospécifiques par ligands; Test immunologique faisant intervenir des lipides, p.ex. le cholestérol
INSERM (INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE) (France)
CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (CNRS) (France)
Inventeur(s)
Perez, Franck
Gouveia, Zelia
Amigorena, Sebastian
Boncompain, Gaelle
Abrégé
A chimeric antigen receptor including: a binding domain, the full DAP 10 protein, the full DAP 12 protein, or a functional variant thereof, and a hook binding domain. Also, a vector system comprising one or more vector including: a nucleic acid comprising a nucleic acid sequence encoding a chimeric antigen receptor and optionally a nucleic acid encoding a hook fusion protein, preferably having a streptavidin core; wherein the nucleic acids are located on the same or on different vectors. Further, a lentiviral vector particles system, host cell and kit including the nucleic acids or vector system, and their use as a medicament, notably for immunotherapy.
C07K 14/435 - Peptides ayant plus de 20 amino-acides; Gastrines; Somatostatines; Mélanotropines; Leurs dérivés provenant d'humains
C07K 14/705 - Récepteurs; Antigènes de surface cellulaire; Déterminants de surface cellulaire
C07K 16/12 - Immunoglobulines, p.ex. anticorps monoclonaux ou polyclonaux contre du matériel provenant de bactéries
C07K 16/28 - Immunoglobulines, p.ex. anticorps monoclonaux ou polyclonaux contre du matériel provenant d'animaux ou d'humains contre des récepteurs, des antigènes de surface cellulaire ou des déterminants de surface cellulaire
C12N 7/00 - Virus, p.ex. bactériophages; Compositions les contenant; Leur préparation ou purification
CENTRE NATIONAL DE LA RECHERCHE SCIENTIFQUE (CNRS) (France)
JUNIA (France)
Inventeur(s)
Collard, Dominique
Fujita, Hiroyuki
Karsten, Stanislav
Tarhan, Mehmet Cagatay
Abrégé
The invention relates to a measuring device (10) for measuring physical characteristics of cells. The device (10) comprises: a microfluidic chip (20) provided with a flow channel (22) for allowing cells to flow through; a manipulator (24) configured to apply deformation force to a cell in a continuous flow; and a sensor (26) configured to sense a physical characteristic of the cell. The manipulator (24) and the sensor (26) are configured to define a width (W2) of the flow channel (22) as a gap formed between them. The manipulator (24) is configured to apply the deformation force to the cell by compressing the cell against the sensor (26).
CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (CNRS) (France)
UNIVERSITE DE PICARDIE JULES VERNE (UPJV) (France)
Inventeur(s)
Russo, Roberto
Stevens, Philippe
Toussaint, Gwenaëlle
Becuwe, Matthieu
Abrégé
Positive electrodes based on organic active material, including molecules of thianthrene as the active material, substituted at specific positions. The electrodes have electrochemical properties enabling their use in a battery, in particular a recyclable battery. The electrodes thus replace the electrodes based on mineral salts that are conventionally used in batteries.
CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (France)
UNIVERSITÉ DE MONTPELLIER (France)
ENSCM - ECOLE NATIONALE SUPERIEURE DE CHIMIE (France)
Inventeur(s)
Montheil, Titouan
Cassenti, Thomas
Subra, Gilles
Mehdi, Ahmad
Poncet, Thierry
Abrégé
The present invention relates to a process for tanning hides using a tanning solution that comprises a silicon compound and is free from metals. The invention also relates to a method for preparing leather that includes a tanning process of this type. The invention also relates to tanned hides obtained by such a tanning process. The invention further relates to a process for detanning the hides obtained by means of the above tanning process.
B01D 53/02 - SÉPARATION Épuration chimique ou biologique des gaz résiduaires, p.ex. gaz d'échappement des moteurs à combustion, fumées, vapeurs, gaz de combustion ou aérosols par adsorption, p.ex. chromatographie préparatoire en phase gazeuse
B01J 20/22 - Compositions absorbantes ou adsorbantes solides ou compositions facilitant la filtration; Absorbants ou adsorbants pour la chromatographie; Procédés pour leur préparation, régénération ou réactivation contenant une substance organique
75.
ELEMENTARY PARTICLE DETECTOR AND ASSOCIATED DETECTION METHOD
CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (France)
Inventeur(s)
Laktineh, Imad
Abrégé
The invention relates to an elementary particle detector (1) comprising: dynodes (10) capable of converting an elementary particle into an avalanche of electrons; conductive grids (30) through which accelerated electrons are able to pass, each grid being defined by a unique electric potential, each unique electric potential being chosen so that the unique electric potential of said conductive grid (30) is strictly lower than the unique electric potential applied to the conductive grid (30) immediately thereafter in the direction of detection (X); at least one signal sensor (50) able to measure an electric signal (S) produced by the accelerated electrons when they pass through the conductive grids (30); and a control unit (90) configured to determine, on the basis of the electric signal (S), a conversion dynode (18) at which the conversion of the elementary particle has taken place. The invention further relates to an elementary particle detection method.
CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (France)
UNIVERSITÉ DE MONTPELLIER (France)
Inventeur(s)
Mechali, Marcel
Akerman, Ildem
Gaborit, Nadège
Abrégé
A method for isolating a mammalian genomic DNA replication origin, the method including: isolating the genomic DNA molecules; identifying 500 bp windows within the DNA molecules; isolating from the genomic DNA molecules the fragments that have a size from 500 pb up 6000 pb; selecting a DNA replication origin that is able, when contained in the DNA of an Eukaryotic cell, to produce nascent DNA, and to initiate DNA replication; and isolating the origin.
CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (France)
Inventeur(s)
Francois, Quentin
Duplat, Bertrand
Haliyo, Sinan
Régnier, Stephane
Zarader, Pierre
Abrégé
A signal tracking system including: one fixation element to be secured to a rigid body part of the patient surrounding a target body part, the fixation element further including a mapping element, one tracker element to be secured to the fixation element to track, in real time, the internal tracker, and a control unit including a memory to store an internal referential and one image displaying the target body part and one fixation element. The control unit is designed to define, inside the internal referential, at least one 3D frame position attached to the at least one fixation element, and to precisely locate each point of the target body part, the control unit is further designed to precisely localize, in real time, the internal tracker inside the target body part.
A61B 5/06 - Dispositifs autres que ceux à radiation, pour détecter ou localiser les corps étrangers
A61B 5/00 - Mesure servant à établir un diagnostic ; Identification des individus
A61B 34/20 - Systèmes de navigation chirurgicale; Dispositifs pour le suivi ou le guidage d'instruments chirurgicaux, p.ex. pour la stéréotaxie sans cadre
CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (France)
INSTITUT GUSTAVE ROUSSY (IGR) (France)
Inventeur(s)
Heidmann, Thierry
Tangy, Frederic
Abrégé
The invention relates to recombinant measles virus expressing Immunodeficiency virus (IV) or HTLV polypeptides, and concerns in particular immunogenic immunodeficiency virus particles expressed by a measles virus and/or virus like particles (VLPs) that contain proteins of at least one immunodeficiency virus or Human T-lymphotropic virus. These particles may be recombinant infectious particles able to replicate in a host after an administration. The invention provides means, in particular nucleic acid constructs, vectors, cells and rescue systems to produce these recombinant infectious particles. The invention also relates to the use of these recombinant infectious particles, in particular under the form of a composition, more particularly in a vaccine formulation, for the treatment or prevention of an infection by HIV or HTLV.
CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (France)
UNIVERSITE GRENOBLE ALPES (France)
Inventeur(s)
Le Goff, Alan
Sorrentino, Ilaria
Abrégé
A method for the detection of polycyclic aromatic hydrocarbons including: a) a step of contacting an aqueous solution including at least one polycyclic aromatic hydrocarbon with a catalyst for the oxidation of polycyclic aromatic hydrocarbons and with an electrode made of a conductive porous material, and b) a step of detecting the anthraquinone that is formed during the previous step through the oxidation of the polycyclic aromatic hydrocarbons.
C12Q 1/26 - Procédés de mesure ou de test faisant intervenir des enzymes, des acides nucléiques ou des micro-organismes; Compositions à cet effet; Procédés pour préparer ces compositions faisant intervenir une oxydoréductase
C12Q 1/00 - Procédés de mesure ou de test faisant intervenir des enzymes, des acides nucléiques ou des micro-organismes; Compositions à cet effet; Procédés pour préparer ces compositions
CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (France)
SORBONNE UNIVERSITÉ (France)
UNIVERSITÉ PARIS CITÉ (France)
ÉCOLE NORMALE SUPÉRIEURE (France)
Inventeur(s)
Bensimon, David
Ducos, Bertrand
Scerbo, Pierluigi
Abrégé
The invention relates to a process for programing a single cell or a group of cells to become malignant, comprising the following steps a) providing cell(s) with the following features: o expressing a dedifferentiation factor, and o comprising an oncogene whose expression is inducible, and b) inducing the expression of said oncogene.
CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (France)
CLERMONT AUVERGNE INP (France)
CENTRE HOSPITALIER UNIVERSITAIRE DE CLERMONT-FERRAND (France)
Inventeur(s)
Bartoli, Adrien
Dousse, Robin
Calvet, Lilian
Samarakoon, Prasad
Abrégé
The invention relates to a method for bringing a virtual three-dimensional model of a target organ, which model is called the 3D model, into register with at least one image of said target organ in a scene, said image being obtained by an endoscope (12), the method in particular comprising: a step of predicting a position and orientation of the target organ relative to the scene; a step of superposing at least one current endoscope image with a see-through projection of the 3D model as a function of the predicted position and orientation, on a display device (18); a step of receiving a command indicating an alignment between the see-through projection of the 3D model and the image of the target organ in the current image; and a step of computing the position and orientation of the target organ in the current image relative to the scene.
G06T 7/33 - Détermination des paramètres de transformation pour l'alignement des images, c. à d. recalage des images utilisant des procédés basés sur les caractéristiques
82.
BLUETOOTH TRANSMISSION FROM A SATELLITE TO A GROUND TELECOMMUNICATION TERMINAL
CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (France)
CYMOON (France)
Inventeur(s)
Ferre, Guillaume
Lattes, Philippe
Abrégé
Device (10) capable of being installed on a satellite (1), comprising telecommunication means (13) for broadcasting information directly to at least one telecommunication terminal (2) on the ground. The information is broadcast according to a Bluetooth Low Energy protocol, and in AD mode. The device can be used in particular for an Earth observation satellite.
H04W 4/06 - Répartition sélective de services de diffusion, p.ex. service de diffusion/multidiffusion multimédia; Services à des groupes d’utilisateurs; Services d’appel sélectif unidirectionnel
H04W 4/90 - Services pour gérer les situations d’urgence ou dangereuses, p.ex. systèmes d’alerte aux séismes et aux tsunamis
CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (France)
UNIVERSITE PAUL SABATIER TOULOUSE III (France)
Inventeur(s)
Rousselle, Mélanie, Laura, Josépha
Fradet, Guillaume
Estournes, Claude, Gilbert, Jean-Pierre
Ansart, Florence
Herisson De Beauvoir, Thomas
Abrégé
The invention relates to a method for producing an abradable ceramic composite coating on a substrate, the method comprising: obtaining (E1) a composition (30) in powder form comprising a matrix powder and a ceramic filler hydrated precursor powder having a lamellar crystallographic structure, wherein the ceramic filler powder represents from 5 to 40% of the combined volume of the matrix powder and the ceramic filler powder; compressing the prepared powder composition at a pressure greater than 150 MPa; and a step of reactive sintering (E2) the obtained powder composition, during which the pressure is maintained at a temperature of less than 550°C, and the particles of the matrix powder in the sintered powder composition have an aspect ratio of 2 or greater. The invention also relates to an abradable ceramic coating obtained according to the method. The invention also relates to a superalloy part for a turbomachine, for example a turbine part, comprising such a coating.
C04B 41/89 - Revêtement ou imprégnation pour obtenir au moins deux revêtements superposés de compositions différentes
B32B 18/00 - Produits stratifiés composés essentiellement de céramiques, p.ex. de produits réfractaires
F01D 11/12 - Prévention ou réduction des pertes internes du fluide énergétique, p.ex. entre étages pour obturations de l'espace entre extrémités d'aubes du rotor et stator utilisant un élément de friction allongé, p.ex. un élément d'usure, déformable ou contraint de façon élastique
C23C 24/08 - Revêtement à partir de poudres inorganiques en utilisant la chaleur ou une pression et la chaleur
F01D 25/00 - "MACHINES" OU MACHINES MOTRICES À DÉPLACEMENT NON POSITIF, p.ex. TURBINES À VAPEUR - Parties constitutives, détails ou accessoires non couverts dans les autres groupes ou d'un intérêt non traité dans ces groupes
C04B 111/00 - Fonction, propriétés ou utilisation des mortiers, du béton ou de la pierre artificielle
84.
TREATMENT OF CONGENITAL STATIONARY NIGHT BLINDNESS USING GENE THERAPY
CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (France)
INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE (INSERM) (France)
Inventeur(s)
Zeitz, Christina
Dalkara, Deniz
Varin, Juliette
Audo, Isabelle
Picaud, Serge
Sahel, José-Alain
Abrégé
The present invention relates to an expression cassette allowing expression of a functional LRIT3 protein in mammal eyes; said expression cassette is inserted in an expression vector, preferably an adeno-associated virus (AAV); accordingly, the present invention further relates to a recombinant adeno-associated virus (AAV) vector carrying a nucleic acid sequence encoding a normal LRIT3 gene, or fragment thereof, under the control of regulatory sequences which express the product of the gene in the ocular cells, a pharmaceutically acceptable composition comprising such a recombinant AAV vector and to its use for the treatment of congenital stationary night blindness
C07K 14/705 - Récepteurs; Antigènes de surface cellulaire; Déterminants de surface cellulaire
A61K 48/00 - Préparations médicinales contenant du matériel génétique qui est introduit dans des cellules du corps vivant pour traiter des maladies génétiques; Thérapie génique
CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (France)
UNIVERSITE DE CAEN NORMANDIE (France)
UNIVERSITE D'ANGERS (France)
ECOLE NATIONALE SUPERIEURE D'INGENIEURS DE CAEN (France)
Inventeur(s)
Lemouchi, Cyprien
Barille, Régis
Travert, Arnaud
Le Pluart, Loïc
Abrégé
An optomechanical transducer, including a tuning fork made of piezoelectric material including two arms, at least one photoactive film partially deposited on at least one part of at least one of the arms of the tuning fork, the at least one photoactive film including photo-switchable molecules, suitable for molecular switching between a first molecular configuration and a second molecular configuration in response to the absorption of light at a defined, so-called photo-isomerisation wavelength, so that the photoactive film undergoes a shape change that induces a change in the stiffness coefficient of the tuning fork is disclosed. A probe is also provided for a frequency modulation atomic force microscope and to such a microscope.
Centre National de la Recherche Scientifique (CNRS) (France)
Inventeur(s)
Ouazzani Chahdi, Jamal-Eddine
Le Goff, Géraldine
Dallery, Jean-Félix
Betzer, Jean-François
Voituriez, Arnaud
Marinetti, Angela
Cacheux, Fanny
Abrégé
The present invention relates to a compound of formula (I) or a pharmaceutically acceptable salt and/or solvate thereof, for use as a drug, especially as an antibiotic. The present invention also relates to a pharmaceutical composition comprising said compound of formula (I) and at least one pharmaceutically acceptable excipient. The present invention further concerns a method of preparation of a compound of formula (I′).
The present invention relates to a compound of formula (I) or a pharmaceutically acceptable salt and/or solvate thereof, for use as a drug, especially as an antibiotic. The present invention also relates to a pharmaceutical composition comprising said compound of formula (I) and at least one pharmaceutically acceptable excipient. The present invention further concerns a method of preparation of a compound of formula (I′).
C07C 49/747 - Composés non saturés comportant un groupe cétone faisant partie d'un cycle contenant des groupes hydroxyle contenant des cycles aromatiques à six chaînons
C07C 45/59 - Préparation de composés comportant des groupes C=O liés uniquement à des atomes de carbone ou d'hydrogène; Préparation des chélates de ces composés à partir de composés hétérocycliques avec l'oxygène comme unique hétéro-atome dans des cycles à cinq chaînons
C07C 49/753 - Composés non saturés comportant un groupe cétone faisant partie d'un cycle contenant des groupes éther, des groupes , des groupes ou des groupes
Centre National de la Recherche Scientifique (CNRS) (France)
Institut National de la Santé et de la Recherche Médicale (INSERM) (France)
Centre Hospitalier Universitaire de Montpellier (France)
Inventeur(s)
Djouad Samri, Farida
Barrere-Lemaire, Stéphanie
Jorgensen, Christian
Abrégé
The present invention relates to an in vitro method for preparing a composition comprising mesenchymal stem cells (MSCs) intended for treating ischemia-reperfusion injury, comprising: a) providing MSCs; b) cultivating MSCs in a culture medium comprising a PPARβ/δ agonist; c) removing the culture medium and washing the MSCs; and d) collecting MSCs in a pharmaceutically acceptable carrier, wherein the pharmaceutically acceptable carrier does not contain a PPARβ/δ agonist. It further relates to MSCs obtained using the method of the invention, as well as their use as a medicament, preferably in the treatment or prevention of ischemia-reperfusion injury, wherein the method of treatment or prevention does not comprise administering a PPARβ/δ agonist to the subject.
A61K 35/28 - Moelle osseuse; Cellules souches hématopoïétiques; Cellules souches mésenchymateuses de toutes origines, p.ex. cellules souches dérivées de tissu adipeux
A61P 9/10 - Médicaments pour le traitement des troubles du système cardiovasculaire des maladies ischémiques ou athéroscléreuses, p.ex. médicaments antiangineux, vasodilatateurs coronariens, médicaments pour le traitement de l'infarctus du myocarde, de la rétinopathie, de l'insuffisance cérébro-vasculaire, de l'artériosclérose rénal
C12N 5/00 - Cellules non différenciées humaines, animales ou végétales, p.ex. lignées cellulaires; Tissus; Leur culture ou conservation; Milieux de culture à cet effet
Centre National de la Recherche Scientifique (CNRS) (France)
Université Paris-Saclay (France)
Inventeur(s)
Albertini, Aurélie
Gaudin, Yves
Raux, Hélène
Belot, Laura
Nikolic, Jovan
Abrégé
The invention relates to an isolated non-naturally occurring protein comprising the amino acid sequence as set forth in SEQ ID NO: 1, and wherein the amino acid in position 8, 47, 209 and/or 354 is substituted by any amino acid different from the amino acid indicated at that position in said sequence SEQ ID NO: 1.
Luxembourg Institute of Science and Technology (Luxembourg)
CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (France)
INSTITUT NATIONAL des SCIENCES APPLIQUEES DE LYON (France)
Centre National d'Études Spatiales (France)
Inventeur(s)
Chemin, Jean-Baptiste
Choquet, Patrick
Colas, Guillaume
Saulot, Aurélien
Yann, Michel
Abrégé
The invention relates to a substrate coated with a coating consisting of molybdenum (Mo), sulfur (S), tantalum (Ta) and oxygen (O) atoms present in the form of one or several compound(s) selected from among the compounds of formula (I):
The invention relates to a substrate coated with a coating consisting of molybdenum (Mo), sulfur (S), tantalum (Ta) and oxygen (O) atoms present in the form of one or several compound(s) selected from among the compounds of formula (I):
MowSxTayOz (I)
wherein w is equal to 0 or 1; x varies from 0 to 2; y varies from 0 to 1 and z varies from 0 to 3; said coating comprising at least 5% at of oxygen and said coating having a dense compact microstructure.
C23C 14/06 - Revêtement par évaporation sous vide, pulvérisation cathodique ou implantation d'ions du matériau composant le revêtement caractérisé par le matériau de revêtement
C23C 14/35 - Pulvérisation cathodique par application d'un champ magnétique, p.ex. pulvérisation au moyen d'un magnétron
90.
METHOD FOR TREATING PROSTATE CANCER AND OTHER EPITHELIAL CANCERS
INSTITUT NATIONAL DE LA SANTÉ ET DE LA RECHERCHE MÉDICALE (France)
UNIVERSITÉ DE MONTPELLIER (France)
INSTITUT RÉGIONAL DU CANCER DE MONTPELLIER (France)
CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (France)
UNIVERSITÉ LIBANAISE (Liban)
Inventeur(s)
Julien, Eric
Alhourani, Fatima
Patouillard, Julie
Aboumerhi, Raghida
Ribeyre, Cyril
Baldin, Véronique
Pourquier, Philippe
Abrégé
The present invention relates to the treatment of cancer. Here, the inventors identified a subset of prostate cancer patients showing an up-regulation of the epigenetic enzymes SUV4-20H1 and SUV4-20H2, two methyltransferases responsible for the di- and tri- methylation of histone H4 at lysine 20 (H4K20me2/3). Consistent with this, the inventors demonstrate that the pharmacological inhibition of both SUV4-20H1 and SUV4-20H2 enzymes by the chemical compound A196 (14) leads to the complete loss of H4K20me2/3 states in prostate cancer cells. Although displaying epigenetic reprograming at genome-wide levels, cancer cells display any significant impairment in their survival or proliferation, thereby demonstrating that the inhibition of SUV4-20H1 and SUV4-20H2 is not toxic per se. Yet, the inventors showed that the pharmacological inhibition of SUV4-2H1 and SUV4-20H2 subtly affects DNA repair mechanisms and the levels of trapped topoisomerase II (TOPO2) complex in silent chromatin regions upon TOPO2 poisons. This creates in vitro as well as in vivo a lethal synergy between A196 and the TOPO2-poison etoposide in prostate cancer cells. Altogether, the results of the inventors showed that the simultaneous inhibition of SUV4-20H and TOPO2 enzymatic activity constitutes indeed a new therapeutic approach for the treatment of advanced or metastatic prostate cancers, which are particularly addicted to SUV4-20H2 and TOPO2 activities. Other cancers could also benefit of this drug combination, since the co-treatment of A196 and etoposide induces similar lethal synergy in other epithelial cancer cells such as breast cancer cell lines. Thus, the present invention relates to a combination of a SUV4-20H inhibitor and a TOPO2 inhibitor for use in the treatment of a cancer in a subject in need thereof.
A61K 31/136 - Amines, p.ex. amantadine ayant des cycles aromatiques, p.ex. méthadone ayant le groupe amino lié directement au cycle aromatique, p.ex. benzène-amine
A61K 31/501 - Pyridazines; Pyridazines hydrogénées non condensées et contenant d'autres hétérocycles
A61K 31/704 - Composés ayant des radicaux saccharide liés à des composés non-saccharide par des liaisons glycosidiques liés à un composé carbocyclique, p.ex. phloridzine liés à un système carbocyclique condensé, p.ex. sennosides, thiocolchicosides, escine, daunorubicine, digitoxine
A61K 31/7048 - Composés ayant des radicaux saccharide et des hétérocycles ayant l'oxygène comme hétéro-atome d'un cycle, p.ex. leucoglucosane, hespéridine, érythromycine, nystatine
A61K 45/06 - Mélanges d'ingrédients actifs sans caractérisation chimique, p.ex. composés antiphlogistiques et pour le cœur
COMPAGNIE GENERALE DES ETABLISSEMENTS MICHELIN (France)
CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (France)
ECOLE SUPERIEURE DE CHIMIE PHYSIQUE ELECTRONIQUE DE LYON (France)
UNIVERSITE CLAUDE BERNARD LYON 1 (France)
Inventeur(s)
Boisson, Christophe
D'Agosto, Franck
Dire, Charlotte
Dronet, Séverin
Langlais, Marvin
Ngo, Robert
Jean-Baptiste-Dit-Dominique, François
Abrégé
The invention relates to triblock polymers of formula A-B-C, in which the symbol A represents a polystyrene block, the symbol B represents a statistical copolymer block having a glass transition temperature of less than -10° C, the statistical copolymer comprising units of a 1,3-diene and more than 50 mol % of ethylene units, and the symbol C represents a polyethylene block having a melting temperature higher than 90°C. The triblock polymers according to the invention have good elastic recovery.
C08F 295/00 - Composés macromoléculaires obtenus par une polymérisation utilisant successivement des catalyseurs de types différents sans désactivation du polymère intermédiaire
C08F 297/08 - Composés macromoléculaires obtenus en polymérisant successivement des systèmes différents de monomère utilisant un catalyseur de type ionique ou du type de coordination sans désactivation du polymère intermédiaire utilisant un catalyseur du type de coordination en polymérisant des mono-oléfines
C08L 53/00 - Compositions contenant des copolymères séquencés possédant au moins une séquence d'un polymère obtenu par des réactions ne faisant intervenir que des liaisons non saturées carbone-carbone; Compositions contenant des dérivés de tels polymères
INSTITUT NATIONAL DE LA SANTÉ ET DE LA RECHERCHE MÉDICALE (France)
CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (France)
CENTRE LEON BERARD (France)
UNIVERSITÉ CLAUDE BERNARD - LYON 1 (France)
Inventeur(s)
Marie, Julien
Preto, Samuel
Tarayre, Hélène
Abrégé
Among the strategies allowing cancer cells to escape the immune system, the presence of Transforming growth factor beta (TGF-β) in the tumor micro-environment (TME) is one of the most potent immunosuppressive mechanisms for many types of tumors. Thus, depleting TGF-β is regarded as a promising potent therapeutic approach to fight cancers, regardless of the type of tumor. However, the major impediment for achieving this objective is that TGF-β belongs to the few cytokines that must be activated once secreted. Moreover, a systemic targeting of TGF-β is associated with profound side effects due to TGF-β ability to sustain the homeostasis of numerous tissues. Hence, selectively targeting of TGF-β activation within the TME appears as a rational approach to boost the anti-tumor response and avoid side effects. The integrin αvβ8 expressed on Tregs specifically promotes TGF-β activation and impairs the anti-CD8 T cell response within the TME of different cancers in both mice and humans. The inventors generated anti-β8 chain of αvβ8 integrin (Itgβ8) neutralizing monoclonal antibodies which specifically bind to Tregs and selectively neutralize the ability of Tregs to activate the TGF-β. Thus, the present invention relates to isolated anti-Itgβ8 neutralizing antibodies which specifically binds to β8 chain of αvβ8 integrin (Itgβ8) expressed on Tregs, and their uses for treating cancer.
C07K 16/28 - Immunoglobulines, p.ex. anticorps monoclonaux ou polyclonaux contre du matériel provenant d'animaux ou d'humains contre des récepteurs, des antigènes de surface cellulaire ou des déterminants de surface cellulaire
93.
USE OF COUMARIN DERIVATIVES AS TOOLS FOR IN VITRO OR EX VIVO DIAGNOSIS OF BACTERIAL EFFLUX
C12Q 1/02 - Procédés de mesure ou de test faisant intervenir des enzymes, des acides nucléiques ou des micro-organismes; Compositions à cet effet; Procédés pour préparer ces compositions faisant intervenir des micro-organismes viables
C12Q 1/18 - Test de l'activité antimicrobienne d'un matériau
94.
DEVICE FOR SPRAYING OZONATED WATER IN AN AGRICULTURAL ENVIRONMENT
INSTITUT NATIONAL DES SCIENCES APPLIQUEES DE TOULOUSE (France)
CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (France)
INSTITUT NATIONAL DE RECHERCHE POUR L'AGRICULTURE, L'ALIMENTATION ET L'ENVIRONNEMENT (France)
INSTITUT NATIONAL POLYTECHNIQUE DE TOULOUSE (France)
Inventeur(s)
Canado, Axel
Hebrard, Gilles
Pages, Marielle
Violleau, Frédéric
Dietrich, Nicolas
Abrégé
The invention relates to a device for spraying ozonated water in an agricultural environment, the device comprising a collar defining a dispensing opening (4) for dispensing both water and ozone together, the water being sprayed by a nozzle (10) set back from the opening, the nozzle being supplied from a tank (7) installed with the device, the ozone gas being dispensed via a gas inlet (22) connected to a device for producing and/or storing gas (9, 13) which is also installed with the device, the gas inlet also being set back in the collar such that the collar defines a chamber (28, 29) for confining the ozone gas emitted around the sprayed liquid in order to allow the sprayed liquid to be enriched with dissolved ozone.
B05B 7/04 - Pistolets pulvérisateurs; Appareillages pour l'évacuation avec des dispositifs permettant le mélange de liquides ou d'autres matériaux fluides avant l'évacuation
B05B 1/34 - Buses, têtes de pulvérisation ou autres dispositifs de sortie, avec ou sans dispositifs auxiliaires tels que valves, moyens de chauffage agencés pour influencer la forme de l'écoulement du liquide ou d'autre matériau fluide, p.ex. pour produire une turbulence
A61L 2/22 - Procédés ou appareils de désinfection ou de stérilisation de matériaux ou d'objets autres que les denrées alimentaires ou les lentilles de contact; Accessoires à cet effet utilisant des substances chimiques des substances à phases, p.ex. des fumées, des aérosols
A61L 9/14 - Désinfection, stérilisation ou désodorisation de l'air utilisant des substances vaporisées ou pulvérisées
B05B 1/04 - Buses, têtes de pulvérisation ou autres dispositifs de sortie, avec ou sans dispositifs auxiliaires tels que valves, moyens de chauffage agencés pour produire un jet, un pulvérisat ou tout autre écoulement de forme ou de nature particulière, p.ex. sous forme de gouttes individuelles de forme plane, p.ex. en forme d'éventail, en forme de lame
95.
MEANS AND METHODS FOR REGULATING INTRACELLULAR TRAFFICKING OF SECRETORY OR CELL MEMBRANE-ANCHORED PROTEINS OF INTEREST
CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (France)
Inventeur(s)
Perez, Franck
Gouveia, Zelia
Abrégé
The present invention relates to a polynucleotide comprising a gene encoding a hook protein and a gene encoding a protein of interest, said protein of interest being either a secretory protein or a cell membrane-anchored protein, wherein:
said gene encoding the hook protein is under the control of a first transcription-activating signal,
said gene encoding the protein of interest is under the control of a second transcription-activating signal, said second transcription-activating signal allowing a lower rate or frequency of transcription initiation than the first transcription-activating signal,
said hook protein is fused to a cellular compartment-retention peptide, and
said protein of interest is fused to a hook protein-binding domain
The present invention relates to a polynucleotide comprising a gene encoding a hook protein and a gene encoding a protein of interest, said protein of interest being either a secretory protein or a cell membrane-anchored protein, wherein:
said gene encoding the hook protein is under the control of a first transcription-activating signal,
said gene encoding the protein of interest is under the control of a second transcription-activating signal, said second transcription-activating signal allowing a lower rate or frequency of transcription initiation than the first transcription-activating signal,
said hook protein is fused to a cellular compartment-retention peptide, and
said protein of interest is fused to a hook protein-binding domain
It also related to vectors comprising the polynucleotide, cells comprising the polynucleotide or the vector and compositions comprising the same. It further relates to methods and uses for modulating the secretion or cell membrane-anchorage of a protein of interest, or for preventing and/or treating a disease in a subject in need thereof.
C12P 21/00 - Préparation de peptides ou de protéines
C07K 14/36 - Peptides ayant plus de 20 amino-acides; Gastrines; Somatostatines; Mélanotropines; Leurs dérivés provenant de bactéries provenant de Streptomyces (G)
CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (France)
NANTES UNIVERSITE (France)
UNIVERSITE DE PICARDIE JULES VERNE (France)
Inventeur(s)
Odobel, Fabrice
Pellegrin, Yann
Baron, Thibaut
Jacquemin, Denis
Sauvage, Fréderic
Naim, Waad
Abrégé
Disclosed is a compound having the following formula (I):
Disclosed is a compound having the following formula (I):
as well as to the use of such as a dye sensitizer.
Disclosed is a compound having the following formula (I):
as well as to the use of such as a dye sensitizer.
Also disclosed is a dye sensitized solar cell including at least one compound of formula (I) as dye sensitizer.
B01J 21/06 - Silicium, titane, zirconium ou hafnium; Leurs oxydes ou hydroxydes
B01J 31/38 - Catalyseurs contenant des hydrures, des complexes de coordination ou des composés organiques contenant en outre des composés métalliques inorganiques non prévus dans les groupes du titane, du zirconium ou du hafnium
B01J 35/00 - Catalyseurs caractérisés par leur forme ou leurs propriétés physiques, en général
C09B 23/01 - Colorants méthiniques ou polyméthiniques, p.ex. du type cyanine caractérisés par la chaîne méthinique
CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (France)
UNIVERSITE CLAUDE BERNARD LYON 1 (France)
ECOLE SUPERIEURE DE CHIMIE, PHYSIQUE, ELECTRONIQUE DE LYON - CPE LYON (France)
Inventeur(s)
Eid, Nadim
Devisme, Samuel
Bonnet, Anthony
Fevrier, Thibaut
Lansalot, Muriel
D'Agosto, Franck
Abrégé
The present invention relates to a process for producing a stable PVDF latex by emulsion polymerization in the absence of fluorinated surfactant, said latex being stabilized by poly(vinyl alcohol) (PVOH).
C08F 261/06 - Composés macromoléculaires obtenus par polymérisation de monomères sur des polymères de monomères contenant de l'oxygène tels que définis dans le groupe sur des polymères d'éthers non saturés
C08L 27/16 - Homopolymères ou copolymères du fluorure de vinylidène
C09D 127/16 - Homopolymères ou copolymères du fluorure de vinylidène
C08L 29/04 - Alcool polyvinylique; Homopolymères ou copolymères d'esters partiellement hydrolysés d'alcools non saturés avec des acides carboxyliques saturés
C08F 2/20 - Polymérisation en suspension utilisant des agents de dispersion macromoléculaires
COMMISSARIAT A L'ENERGIE ATOMIQUE ET AUX ENERGIES ALTERNATIVES (France)
UNIVERSITÉ GRENOBLE ALPES (France)
INSTITUT POLYTECHNIQUE DE GRENOBLE (France)
CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (France)
Inventeur(s)
Savin, Valentin
Goswami, Ashutosh-Kumar
Mhalla, Mehdi
Abrégé
The present invention concerns a method and a system of fault tolerant preparation of quantum polar code states, comprising: -a set of single qubit Pauli measurement circuits (3) configured to prepare an initial quantum system 5 of N = 2n single-qubit states associated to an initial quantum base, -a set of two qubit Pauli measurement circuits (7) configured to recursively prepare a quantum polar code |q2n)s °f codelength N = 2n, wherein at each recursive level k, where k = 1 to n, a set of 2n/2k quantum polar code states ||<72fc) j(k) = 1 to 2n/2k of codelengths 2k, siW referenced by corresponding sets Sj^ of indices comprising first and second sets of frozen indices = [17, ■ ■■, i7(k)} and X7(k) = {(i + !);(/<),..., 27k k)} is prepared, each quantum polar code state |q2k) being prepared by the application of two qubit Pauli measurement P ® P circuits on two equivalent polar code states 2^ ) 01 aanndd belonging to the output of the antecedent recursive level k — 1 and referenced by two corresponding sets of iinnddiicceess
G06N 10/70 - Correction, détection ou prévention d’erreur quantique, p.ex. codes de surface ou distillation d’état magique
G06N 10/40 - Réalisations ou architectures physiques de processeurs ou de composants quantiques pour la manipulation de qubits, p.ex. couplage ou commande de qubit
CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (France)
Inventeur(s)
Cailleau, Antoine
Klotz, Alain
Abrégé
The invention relates to an angular positioning module (1) for a positioning system for an optical bench, the angular positioning module (1) comprising: a fixed frame (5); a rotating shaft (7); a rotary motor (11); a transmission device (17) being provided with a pulley (19) mounted on the output rod (13) of the rotary motor (11) so as to be coupled in rotation therewith, with a wheel (21) mounted on the rotating shaft (7) so as to be coupled in rotation therewith, and with a cable wound on the one hand around the pulley (19) and on the other hand around the wheel (21) such that the pulley (19) and the wheel (21) are connected by two separate strands of the cable, the rotation of the pulley (19) causing the winding of a first strand and the simultaneous unwinding of a separate second strand around the pulley (19), and vice versa.
G02B 7/00 - Montures, moyens de réglage ou raccords étanches à la lumière pour éléments optiques
F16H 19/06 - Transmissions comportant essentiellement et uniquement des engrenages ou des organes de friction et qui ne peuvent transmettre un mouvement rotatif indéfini pour convertir un mouvement rotatif en mouvement alternatif et vice versa comportant un organe flexible sans fin
100.
ELECTRICAL ENERGY STORAGE MODULE HAVING INTEGRATED POWER CONVERSION MEANS, AND ELECTRICAL ENERGY STORE INCORPORATING SAME
CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (France)
CONSERVATOIRE NATIONAL DES ARTS ET METIERS (France)
CY CERGY PARIS UNIVERSITE (France)
SAFT (France)
SORBONNE UNIVERSITE (France)
UNIVERSITE PARIS-SACLAY (France)
ÉCOLE NORMALE SUPÉRIEURE PARIS-SACLAY (France)
Inventeur(s)
Roy, Francis
Boulay, Marc
Peuchant, Thomas
Narbonne, Alexandre
Herpe, David
Labrousse, Denis
Laboure, Eric
Abrégé
The invention relates to an electrical energy storage module (M1-ln) which comprises a plurality of elementary storage cells (C1 to C12). According to the invention, the module comprises at least one cell unit (U1-1, U1-2) including a plurality of elementary storage cells connected in series (C1 to C6; C7 to C12) and integrated power-switching means (P1, S1; P2, S2) dedicated to this cell unit, delivering, between two power output terminals (B1, B2) of the cell unit, a positive DC voltage, a negative DC voltage, a zero voltage or a high impedance state, depending on a command received by the cell unit.